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5Women don’t want to hear what you think. 
Women want to hear what they think – in a deeper voice. 
Bill Cosby
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7ABSTRACT
Background: Bell’s palsy is an acute peripheral facial nerve dysfunction with 
unknown etiology, causing weakness or paralysis of the mimic muscles of the face. 
The disease can cause disfi gurement of the face, impair the ability to eat, drink and 
speak, and seriously affect the patient’s quality of life. Physicians have searched 
for tests or clinical signs that can predict the outcome of Bell’s palsy but none have 
proven powerful enough. Studies also show several methodological differences and 
interpretation of results is diffi cult. In addition, validated instruments measuring 
quality of life aspects in these patients in Swedish have not been available.
Aims: To examine the effect of different analysis methods on a Bell’s palsy study, 
to fi nd prognostic clinical signs for non-recovery in Bell’s palsy using the Sunny-
brook facial grading scale, and to translate and validate the Facial Disability Index 
(FDI) and Facial Clinimetric Evaluation (FaCE) scale questionnaires in Swedish.
Data: Data for papers I-III were extracted from a prospective, controlled multi-
center study including 829 patients with Bell’s palsy. Patients were randomized to 
treatment with prednisolone and/or valacyclovir or placebo. In paper IV, 93 patients 
with stable peripheral facial palsy had their facial function assessed with House-
Brackmann and Sunnybrook scales and answered FDI and FaCE-scale questionnai-
res on two occasions with a 2-week interval. 
Results and conclusions: The choice of statistical method and defi nition of com-
plete recovery substantially infl uence the calculated rate of recovery. These results 
emphasize the caution that must be exercised when interpreting clinical results in 
reported Bell’s palsy studies. Early deterioration in Sunnybrook scores between 
baseline and fi rst follow-up at days 11-17 is found to be a negative prognostic fac-
tor for complete recovery at 12 months. Early prednisolone treatment reduces this 
deterioration and improves outcome in patients with early deterioration. Sunny-
brook grading at 1 month can accurately predict non-recovery (Sunnybrook< 70) 
at 12 months in Bell’s palsy. A prediction model and a simple-to-use risk curve for 
identifying patients at risk for sequelae based on the Sunnybrook score at 1 month 
are presented and both can be used in clinical practice. The Swedish versions of 
the FDI and FaCE-scale show high reliability and validity, and the questionnaires 
can be used for clinical evaluation and for studies on patients with peripheral facial 
palsy in Sweden.
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INTRODUCTION
Background 
Peripheral facial palsy is the most frequent cranial neuropathy and can originate 
from various kinds of damage to the seventh cranial nerve, including its motor nu-
cleus (Roob et al. 1999). A peripheral palsy of the facial nerve can cause not only a 
distressing disfi gurement of the face, but also impair the ability to communicate by 
facial expression and articulation. An impairment of the motor function of the facial 
mimic muscles may also cause an inability to eat, drink and speak in an agreeable 
manner, thereby causing embarrassment and social isolation. This may seriously 
affect the individual’s possibilities to function in his or her social environment. 
Bell’s palsy is the most common form of peripheral facial palsy in adults (Peitersen 
2002). For decades, physicians have searched for tests or clinical signs that can 
predict the outcome of Bell’s palsy. However, studies show several methodological 
differences and interpretation of the results is diffi cult. The main purpose of this 
thesis is to examine prognostic signs for recovery in Bell’s palsy and to study the 
effect of different analysis methods on Bell’s palsy trials. 
Although several studies regarding Bell’s palsy have been performed in Sweden, 
validated instruments for measuring quality of life aspects in this patient group in 
Swedish are still lacking.  The second purpose of this work is therefore to translate 
and validate two instruments for measuring quality of life status in patients with 
peripheral facial palsy.  
Anatomy
The greater part of the VIIth cranial nerve, also termed the facial nerve, is compo-
sed of motor fi bers to the mimic muscles regulating facial expression. The facial 
nerve also carries parasympatic fi bers to the submandibular, sublingual, and lacri-
mal glands, taste fi bers from the anterior two-thirds of the tongue, sensory fi bers 
from membranes of the pharynx, nose and hard and soft palate, and sensation from 
the skin in the region of the external ear (May M 2000). 
Signals for voluntary movement of the facial mimic muscles originate in the mo-
tor cortex and pass via the corticobulbar tract in the internal capsule to the facial 
motor nuclei in the caudal lateral pons. The majority of the fi bers cross over in the 
pons and reach the facial nucleus of the opposite side, but some diverge toward 
the ipsilateral facial nucleus. Facial nuclei therefore receive input from both sides 
of the cerebral cortex (Malone and Maisel 1988). The forehead and the orbicularis 
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oculi muscles receive fi bers from both the contralateral and ipsilateral motor cortex, 
while the lower muscles of facial expression receive fi bers from only the contrala-
teral motor cortex. This explains why central (upper motor neuron) and peripheral 
(lower motor neuron) lesions present differently (Malone and Maisel 1988; May M 
2000). 
Before emerging from the pons, fi bers make a loop around the nuclei of cranial 
nerve VI and traverse through the internal auditory canal together with cranial ner-
ve VIII (the vestibulo-cochlerar nerve). The sensory root of the facial nerve runs 
separate from the motor root between the brainstem and the internal acoustic canal 
and is often called nervus intermedius (Gilchrist 2009). 
After entering its own bony circuitous tunnel, the fallopian canal, the nerve makes 
two bends, thus dividing the canal into three segments: the labyrinthine, the tympa-
nic (horizontal), and the mastoid (vertical) (Roob et al. 1999). The labyrinthine part 
ends at the geniculate ganglion where the nerve makes its fi rst external genu. Within 
the canal, some visceral motor fi bers become the greater petrosal nerve, which leads 
to the sphenopalatine ganglia from where it supplies the lacrimal, nasal and palatine 
Figure 1. Central and peripheral facial palsy. From Am Fam Physician. 2007 Oct 
1;76:997-1002. Bell’s palsy: Diagnosis and Management, Tiemstra and Khatkhate
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glands. In the tympanic segment, a second branch of the facial nerve arises; the 
nerve to the stapedius muscle that regulates the stapedial refl ex and thus protects the 
inner ear from harmful noise. The facial canal then makes its second external bend 
in the mastoid segment, where visceral branches form the chorda tympani, which 
provides innervation to the submandibular and sublingual salivary glands and taste 
to the anterior two thirds of one side of the tongue (Gilchrist 2009). 
The facial nerve leaves the skull through the stylomastoid foramen between the 
mastoid and the styloid processes. Following its emergence from the skull, it gi-
ves off the posterior auricular nerve to provide sensation to the periauricular area. 
The facial nerve then runs in an arciform course to supply the motor branch of the 
stylohyoid muscles and the posterior belly of the digastric muscle, before entering 
the posterior border of the parotid gland. There it fi nally divides into its terminal 
branches, the temporofrontal, zygomatic, buccal, marginal mandibular and cervical 
branches that regulate the movement of the face (Malone and Maisel 1988). 
The labyrinthine section of the fallopian canal has been claimed to be the narrowest 
part (Dumitru et al. 1988) and the nerve is believed to be most vulnerable to stretch 
and compression at this point (Fisch and Felix 1983).
Figure 2. Facial nerve. Pictures by Dr Kedar K, Dr Adour K, and Steadman E.
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Etiology of peripheral facial palsy
The long intra- and extra-cranial course of the facial nerve exposes the nerve to a 
broad battery of diseases potentially causing peripheral facial palsy. The etiology 
of peripheral facial palsy can be infections, trauma, vascular lesions and tumors 
among others (Valls-Sole 2007). Most frequently identifi able causes of peripheral 
facial palsy are listed in Table I.
TABLE I. Identifi able etiologies of peripheral facial palsy. Modifi ed from Roob et 
al. Eur Neurol 1999;41:3-9 
Traumatic and post-surgical Human immunodefi ciency virus
Temporal bone fracture CMV
Middle ear surgery Mycoplasma
Mastoidectomy Meningitis
Parotid gland surgery Guillain-Barré syndrome
Penetrating wound Idiopathic cranial polyneuropathy
  Otitis media (acute and chronic)
Tumor and other compression Heerford syndrome (sarcoidosis)
Neuroma/neurinoma Melkersson-Rosenthal syndrome
Meningioma 
Choleasteatoma Pontine lesions
Parotid gland tumor Infl ammatory - demyelinating (multiple  
Hemangioma sclerosis)
Metastasis Vascular
  Tumor
Infection and infl ammation, 
demyelination 
Herpes zoster (Ramsey Hunt syndrome) Miscellaneous
Lyme disease Diabetes mellitus
Herpes simplex 
Bell’s palsy
Bell’s palsy is unilateral weakness or paralysis of the face due to acute peripheral 
facial nerve dysfunction with no readily identifi able cause and with some recovery 
of function within six month (May and Hughes 1987). Named after Sir Charles Bell 
(1774-1842), who in the 1820s described the syndrome along with the anatomy and 
function of the facial nerve, it is the most common cause of peripheral facial palsy 
(Holland and Weiner 2004).
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The average annual incidence of Bell’s palsy is 25–30 per 100,000 individuals (Ya-
nagihara 1988; Peitersen 2002) with the highest incidence in patients aged 15-45 
(Peitersen 2002). No gender, side, annual or seasonal differences have been noted 
in most studies (Peitersen 1982; Yanagihara 1988) and no racial predilection has 
been established (Dumitru et al. 1988). 
The onset of Bell’s palsy is sudden and usually evolves rapidly during a period of 1 
to 7 days (Chow et al. 2002; Tiemstra and Khatkhate 2007; Melvin and Limb 2008), 
but it may also progress more slowly, reaching maximum weakness up to 1 to 3 
weeks after onset (Adour et al. 1985; May and Hughes 1987; Linder et al. 2010). 
Etiology of Bell’s palsy
The etiology of Bell’s palsy remains obscure and there are no clinical, radiological 
or laboratory tests that can diagnose the disease. On the contrary, diagnosis should 
be made after exclusion of all other possible causes of peripheral facial palsy. Seve-
ral theories concerning the etiology have been proposed including genetic, vascu-
lar, infective, and autoimmune processes (Roob et al. 1999). Herpes simplex type 
I (HSV-1) and varicella zoster are two viruses believed to be a plausible etiologic 
factor for the majority of reported Bell’s palsies (Dumitru et al. 1988). McCormick 
(McCormick 1972) published a hypothesis suggesting that reactivation of HSV-1 
causes infl ammation and edema in the bony fallopian canal and results in periphe-
ral facial palsy due to compression. His theory was supported by earlier results 
from serological studies of HSV antibodies by Adour and co-workers (Adour et 
al. 1975). In a histopathological study of the facial nerve performed by Liston and 
Kleid, (Liston and Kleid 1989), the entire nerve was found to be infi ltrated by in-
fl ammatory cells. Myelin breakdown, axonal changes, and edema were present, 
suggesting viral neuritis. Increased numbers of HSV genome fragments detected 
by polymerase chain reaction (PCR) were seen in the saliva of patients with Bell’s 
palsy (Furuta et al. 1998). PCR also identifi ed such fragments in human geniculate 
ganglia at autopsy (Takasu et al. 1992; Burgess et al. 1994). Murakami et al. detec-
ted HSV-1 DNA in endoneurial fl uid from the facial nerve and posterior auricular 
muscle from patients with Bell’s palsy during decompression surgery (Murakami 
et al. 1996). Varicella zoster virus infection has also been suggested as the cause of 
Bell’s palsy, even without eruptions of the skin, so-called zoster sin herpete (Adour 
1994; Furuta et al. 2000; Lee et al. 2012).
However, other studies have failed to support the viral theory (Rowlands et al. 
2002; Linder et al. 2005; Stjernquist-Desatnik et al. 2006) and the etiology of Bell’s 
palsy still remains unclear. 
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Treatment 
Medical treatment
The medical treatment of Bell’s palsy used to be highly controversial and different 
therapeutic regimens have been suggested over the decades. Because the disease 
is known to be associated with edema and infl ammation of the facial nerve (Ya-
nagihara et al. 2000), corticosteroid treatment, particularly in the early stages, has 
been an obvious possibility (Kennedy 2010). This was believed to reduce edema, 
swelling and subsequent compression of the nerve within the facial canal (Roob et 
al. 1999). However, the proposal of corticosteroids as the treatment of choice was 
mainly based on non-randomized comparisons (Adour et al. 1972). Since then, nu-
merous authors of clinical series have both espoused and condemned corticosteroid 
therapy with, what appeared to both proponent groups, to be equally convincing 
arguments (Burgess et al. 1984).
With growing support for herpes simplex virus as an etiology for Bell’s palsy 
(McCormick 1972; Murakami et al. 1996) the use of antiviral agents emerged. Anti-
viral medication was intended to eradicate the infectious agent, and corticosteroids 
could then reduce the swelling of the facial nerve. Results of studies by Hato et al 
report that a combination of valacyclovir and prednisolone was more effective than 
prednisolone alone for complete recovery (Hato et al. 2007). However, other ran-
domized clinical trials could not verify these results (Sullivan et al. 2007; Engstrom 
et al. 2008).
The latest Cochrane database review concluded that the available evidence from 
randomized controlled trials shows signifi cant benefi t from treating Bell’s palsy 
with corticosteroids (Salinas et al. 2010). Corticosteroids alone improve rate of 
recovery and the proportion of people who make a full recovery, and reduce cosme-
tically-disabling sequelae, motor synkinesis, and autonomic dysfunction compared 
with placebo or no treatment (Holland and Bernstein 2011). Treatment is likely to 
be more effective when started within 72 hours of onset, and less effective after 7 
days (Holland and Bernstein 2011).
Furthermore, high-quality evidence from randomized controlled trials of herpes 
simplex antivirals for the treatment of Bell’s palsy showed no signifi cant benefi t 
from antivirals compared to placebo. (Lockhart et al. 2009). There is no evidence of 
a clinically-important additive effect of adding antivirals to corticosteroid therapy 
(Engstrom et al. 2008; Holland and Bernstein 2011).
Some authors have recommended prednisolone treatment to prevent progression of 
paresis from a mild to severe form (Adour 1991), but it is still unclear whether early 
prednisolone treatment could prevent deterioration of incomplete palsy to complete 
clinical paralysis (May et al. 1976; Linder et al. 2010).
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Surgical treatment
Decompression surgery: As the proposed pathophysiology involves entrapment of 
the nerve, some surgeons have suggested surgical decompression of the nerve as a 
suitable management option. In 1932, Balance and Duel reported the fi rst recorded 
attempt at surgical decompression of the facial nerve for Bell’s palsy (Duel 1934). 
Over the following decades, different proposed methods for decompression ope-
rations have been reported and their timing has also varied from three months to 
surgery immediately after onset of palsy (Fisch and Esslen 1972; May and Hawkins 
1972) . 
Since randomized controlled trials have produced only very low-quality evidence, 
there is insuffi cient evidence to support surgical decompression for the manage-
ment of Bell’s palsy (McAllister et al. 2011). This, together with the inherent danger 
of damaging the facial nerve and other ear structures during the decompression pro-
cedure, has made this surgery rare in the management of Bell’s palsy. In Sweden to-
day, decompression surgery is rarely undertaken in the management of the disease. 
Reconstructive surgery/treatment: Other surgical procedures can be categorized 
into dynamic versus static, and are mainly undertaken by plastic reconstructive sur-
geons. In cases where facial muscles can be re-innervated, nerve transfer to ‘baby-
sit’ facial muscles can be performed. These dynamic procedures include ipsilateral 
nerve grafts, nerve transfers and cross-facial nerve grafts. This concept of facial 
reanimation implies that there is a possibility of preventing, minimizing, or slowing 
down the denervation effects on the facial musculature, and the techniques are be-
lieved to be best employed as soon as possible after onset of facial paralysis (Ros-
son and Redett 2008). Other dynamic procedures include regional and free muscle 
transfers.
Static procedures, undertaken when sequelae are already obvious, involve facial 
slings to eyelids and mouth, gold/platinum weights to upper eyelids, eyelid proce-
dures, brow lifts and botox (Rosson and Redett 2008). Optimal reconstruction of 
the completely paralyzed face usually requires multiple surgeries with both dyna-
mic and static procedures (Robey and Snyder 2011). 
Physical therapy 
Bell’s palsy is commonly treated by various physical therapy strategies and advice. 
Exercise therapy is the most commonly used, but thermal methods, electrotherapy, 
massage and biofeedback are other forms that have been used (Peitersen 2002; 
Beurskens and Heymans 2004; Teixeira et al. 2011).
The effectiveness of facial exercise therapy for facial palsy has been debated in 
systematic reviews and the mechanism of action is still not totally explained. The 
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Cochrane Database Systematic Review made by Teixeira and co-workers in 2011 
concludes that high-quality evidence to support signifi cant benefi t or harm from 
any physical therapy for idiopathic facial paralysis is lacking. There is, however, 
low-quality evidence that tailored facial exercises can help improve facial function, 
mainly for people with moderate paralysis and chronic cases, and that facial exer-
cise reduces sequelae in acute cases (Teixeira et al. 2011).
In their systematic review and meta-analysis, Pereira et al. concluded that mime 
therapy can improve functionality for patients with facial palsy (Pereira et al. 2011). 
Baricich et al. also found low-level evidence that mime therapy could be effective 
in improving functional outcome in patients with peripheral facial palsy. However, 
evidence of specifi c treatment addressed to specifi c cause is lacking and no evi-
dence is available on the timing of intervention with respect to time of onset. Well-
designed randomized controlled trials are therefore required to evaluate the effect 
of rehabilitation in patients with facial palsy (Baricich et al. 2012).
Sequelae and recovery rates
Most Bell’s palsy patients are believed to recover well but persistent peripheral 
facial palsy can be a devastating handicap. Apart from negatively affecting facial 
appearance, weakness of the facial musculature can result in diffi culty in eating, 
drinking, speaking, and conveying intimate human emotions and communication 
signals. Disabling secondary defects also include eye dryness and irritation, taste 
disturbances, stapedius muscle problems resulting in over-sensitivity to loud noise, 
muscle spasm, and facial pain. The most troublesome sequelae for patients are the 
associated movements, so-called synkinesis, and contractures that give the patient a 
feeling of stiffness in the facial muscles (Peitersen 2002). The social and psycholo-
gical consequences of peripheral facial palsy can be signifi cant (Macgregor 1990). 
Earlier Bell’s palsy trials have reported varying rates of facial recovery in both 
treated and untreated patients. In the large, non-controlled study on the spontaneous 
course of Bell’s palsy that included 1,701 cases studied over a period of 25 years, 
Peitersen reported that about 70% of the patients recovered without medical treat-
ment within 6 months (Peitersen 2002). Sequelae were slight in 12% of the patients, 
mild in 13% and severe in 4%. He concluded that no treatment, even that including 
prednisone, was able to improve prognosis. 
In contrast, two recent large Bell’s palsy trails both concluded that prednisolone 
does improve restitution of facial function, (Sullivan et al. 2007; Engstrom et al. 
2008). Sullivan and coworkers reported complete recovery of facial function in 
over 90% of patients treated with prednisolone (Sullivan et al. 2007) and in the 
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study of Engström et al., the corresponding proportions of patients with complete 
recovery were 72% (Engstrom et al. 2008). In two recent Japanese trials, treatment 
with prednisolone resulted in recovery rates of 80% and 90% respectively (Kawa-
guchi et al. 2007) (Hato et al. 2007). In the retrospective clinical study by Mant-
sopoulos, 73% of patients treated with prednisolone had a satisfactory outcome 
(Mantsopoulos et al. 2011) compared to the prospective study by Takemoto et al. 
where full recovery was seen in 94% of patients treated with both prednisolone and 
valaciclovir (Takemoto et al. 2011). 
All above-mentioned studies have methodological differences with different facial 
grading systems, different follow-up times and different statistical methods and 
defi nitions of complete recovery. The impact of study design on recovery rates has 
been a subject of discussion because studies with similar treatments report varying 
recovery rates (Gilden and Tyler 2007; Davenport et al. 2008). 
Are there any prognostic factors for outcome?
A leading prognostic problem is the diffi culty in predicting the fi nal grade of de-
nervation early enough in the development of the disease. Bell’s palsy lesions may 
result in temporary neural blockade (neurapraxia) or axonal destruction with Walle-
rian degeneration (axonotmesis, neurotmesis). Early in disease evolution, the prog-
nosis is uncertain because the pathologic process producing paralysis may continue 
for 1-3 weeks (Linder et al. 2010).
Electrophysiology 
Several electrophysiological methods have been used in the prognosis of Bell’s 
palsy, including minimal- and maximal nerve excitability testing, blink refl ex, elec-
tromyography (EMG) and electroneurography (ENoG) (Chow et al. 2002). Among 
these tests, ENoG has shown to be the most powerful tool in predicting the progno-
sis of Bell’s palsy and other acute peripheral facial palsies (Thomander and Stalberg 
1981; May et al. 1983; Valls-Sole 2007; Mantsopoulos et al. 2011; Takemoto et al. 
2011). 
ENoG for prognostic purposes in Bell’s palsy was popularized by Fisch (Fisch 
1984). The procedure includes stimulating the facial nerve peripherally, recording 
the compound muscle action potential of the affected side, and expressing that as a 
percentage of the non-affected side. Individuals who demonstrate complete palsy 
and 10% or less of the normal evoked response within the fi rst 2 weeks were belie-
ved to have an 80% risk of unsatisfactory recovery (Dumitru et al. 1988).
Although ENoG has the advantage of recordable quantitative and reproducible re-
sults, reliable results are dependent on skilled personnel being able to operate the 
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special equipment with a standardized method since this can infl uence the test re-
sults (Gantz et al. 1984). Furthermore, ENoG cannot give precise information on 
the type of injury that occurred in the nerve (Fisch 1984). Wallerian degeneration in 
the distal segment of the nerve takes at least 72 hours to become apparent after an 
acute injury to the facial nerve. It is therefore recommended that ENOG should not 
be performed until at least 3 days after the onset of facial palsy. Some users choose 
to establish ENoG as a prognostic indicator between 5 to 14 days after onset (Chow 
et al. 2002; Kress et al. 2004; Valls-Sole 2007). Patients with an uncertain prognosis 
were also recommended daily serial tests to assess prognosis, particularly between 
the seventh and fourteenth day after onset of the palsy (Esslen 1977; Fisch 1984; 
Chow et al. 2002). This can cause a severe problem in the clinical setting, since 
access to these neurophysiological tests is often limited (Kasse et al. 2005).
As a result, other factors that can predict prognosis have been sought in studies 
based on clinical evaluation of acute symptoms and signs, concurrent medical di-
seases, age, and radiological investigations. 
Clinical parameters for prognosis
Many reports have examined the infl uence of different parameters on the fi nal out-
come of Bell’s palsy. Epidemiologic factors include: age (Kerbavaz et al. 1983; 
Peitersen 2002; Ikeda et al. 2005; Kasse et al. 2005), clinical severity of the initial 
palsy (Katusic et al. 1986; Gavilan et al. 1988; Smith et al. 1988; Peitersen 2002; 
Ikeda et al. 2005), severity of palsy 1 month after onset (Ikeda et al. 2005), early 
beginning of remission (Smith et al. 1988), otalgia or postauricular pain (Katusic et 
al. 1986; Gavilan et al. 1988; Smith et al. 1988; Peitersen 2002; Berg et al. 2009), 
and previous ipsilateral palsy (Gavilan et al. 1988). 
Old age is often referred to as a negative prognostic factor, but in the work of Mant-
sopoulos et al., age was not statistically signifi cant in the long-term prognosis of 
Bell’s palsy (Mantsopoulos et al. 2011).
The work of Katusic et al. identifi ed hypertension as an important risk factor for 
incomplete recovery (Katusic et al. 1986). Peitersen, on the other hand, did not fi nd 
more frequent or severe palsies  in hypertensive patients (Peitersen 2002).
MRI 
In the literature, some claim magnetic resonance imaging (MRI) data to be a valid 
method of predicting outcome (Brugel et al. 1993; Kress et al. 2004), but MRI has 
mainly been deemed to be an unreliable method for prognostifi cation (Kohsyu et 
al. 1994; Brandle et al. 1996; Engstrom et al. 1997; Mineta et al. 1997; Burmeister 
et al. 2011).
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Although several studies have investigated these clinical predictive factors, many 
factors remain inconclusive and not powerful enough in the clinical situation. Ad-
ditional clinical prognostic tools are therefore needed (Yeo et al. 2007; Ushio et al. 
2008).
Grading scales 
Clinicians require an objective, reliable and valid clinical tool to accurately de-
scribe a patient’s facial function, to monitor status over time, and to assess and 
communicate the course of recovery and the effects of treatment (Croxson et al. 
1990; Ross et al. 1996). For a grading system to have clinical usefulness, it must 
be easy to administer, require little time or equipment, yet be sensitive enough to 
detect clinically important changes (Ross et al. 1996). Secondary defects such as 
synkinesis, contracture, and hemifacial spasms may affect facial appearance and 
function and can be considered in the assessment. In the review of House in 1983, 
facial grading scales were divided into three different categories: gross, regional 
(weighted or unweighted) and specifi c (House 1983). 
The general scales are called ‘gross’ because they consider overall facial function. 
The primary purpose of gross scales is description; they categorize patients in a 
simple and practical way without specifi c details about facial function. Gross scales 
have been proposed by Botman and Jongkees (Botman and Jongkees 1955), May 
(May 1970), Peitersen (Peitersen 1982) and House (House and Brackmann 1985).
In a regional system, the assessor scores different areas of facial function indepen-
dently. In a weighted regional scale, certain areas of the face are considered less 
important because they are deemed to be less functionally or cosmetically relevant. 
Regional scales have been devised by several authors (Yanagihara 1976; Lewis and 
Adour 1995; Ross et al. 1996). In addition to these main systems, different specifi c 
scales that address the presence or absence of various associated symptoms also 
exist (Stennert et al. 1977; Burres and Fisch 1986; Murty et al. 1994).
The House-Brackmann system, based on a 6-graded score where I is normal fun-
ction and VI total paralysis, offers a gross evaluation of facial motor function and 
evaluation of sequelae. Its basic purpose is to rate patient’s facial function according 
to general categories and not to give specifi c details about facial function (House 
1983; House and Brackmann 1985). In 1985, the Facial Nerve Disorder Committee 
of the American Academy of Otolaryngology - Head and Neck Surgery adopted the 
House-Brackmann grading scale as a universal standard for grading facial nerve 
recovery (House and Brackmann 1985). It has since become the most used scaling 
system for facial nerve disorders in the USA and Europe. However, the scale has 
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been criticized for not being sensitive enough to document clinically signifi cant 
changes in facial function over time (Ross et al. 1996) and for being prone to inter-
observer variation (Croxson et al. 1990; Kanerva et al. 2006). 
TABLE II. The House-Brackmann facial grading scale
Grade Description Characteristics
I Normal Normal facial function in all areas
II Mild dysfunction Slight weakness noticeable on close inspection; 
  may have very slight synkinesis
III Moderate dysfunction Obvious but not disfi guring difference between 
  2 sides; noticeable but not severe synkinesis, 
  contracture or hemifacial spasm; complete eye 
  closure with effort
IV Moderately severe  Obvious weakness or disfi guring asymmetry; normal
 dysfunction symmetry and tone at rest; incomplete eye closure
V Severe dysfunction Only barely perceptible motion; asymmetry at rest
VI Total paralysis No movement
In 1996, Ross et al. proposed a grading system, the Sunnybrook facial grading 
system, that reports results in a more continuous manner and with a wider response 
range than the House-Brackmann grades (Ross et al. 1996). This regionally-weigh-
ted system includes evaluation of resting symmetry, degree of voluntary move-
ments, and synkinesis to form a composite score from 0 to 100, where 0 is complete 
paralysis and 100 indicates normal function (Ross et al. 1996).
Due to its demonstrated improved sensitivity and reliability, use of the Sunnybrook 
facial grading system has been advocated when the intention is to monitor change 
in facial function (Chee and Nedzelski 2000; Kanerva et al. 2006). The intra-rater 
and inter-rater reliability of the system has been reported to be high when applied 
both by novice and expert users (Hu et al. 2001).
The regional unweighted Yanagihara system assesses 10 areas of facial function. 
Each function is scored from 0 to 4, giving a maximum score of 40. The scale does 
not include any secondary effects. The Yanagihara scale is the most widely used 
system in Japanese studies for evaluating facial nerve function in peripheral facial 
palsy (Satoh et al. 2000). 
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TABLE III. The Sunnybrook Facial Grading scale
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Peripheral facial palsy and quality-of-life
Health-related quality-of-life is the component of overall life quality that is deter-
mined primarily by the person’s health and may be infl uenced by clinical interven-
tion. It is a broad multi-dimensional concept that usually includes self-reported 
measures of physical and mental health. 
Most of the measurement methods used in Bell’s palsy today are the above-men-
tioned physician-ranking scales that quantify impairment of facial posture and mo-
vement. Although both the House-Brackmann and Sunnybrook scales describe the 
severity of facial palsy, neither capture the patient’s perception of their outcome and 
neither address how this handicap may affect the patient’s quality-of-life.
Facial nerve dysfunction may be classifi ed into two components: facial impairment, 
which describes the anatomical abnormality, and facial disability, which pertains 
to the functional and social defi cits caused by the impairment (Saito and Cheung 
2010). 
A number of existing patient-reported instruments measure quality-of-life outco-
mes in peripheral facial palsy patients. These validated instruments measure and 
describe facial disability related to dysfunction. The most used and best-validated 
questionnaires are the Facial Disability Index (FDI) and the Facial Clinimetric Eva-
luation (FaCE) scale (Ho et al. 2012). FDI, developed by physical therapists at the 
Facial Nerve Center of the University of Pittsburgh, includes aspects of the mouth, 
eye and entire face, as well as the infl uence of the palsy on emotions and every-
day activity (VanSwearingen and Brach 1996). Patients report their impairment and 
disability by answering 10 questions divided into two domains: physical function 
and social/well-being function. The FaCE-scale, developed by researchers at the 
Baylor College of Medicine, Houston, Texas, also measures facial impairment and 
disability (Kahn et al. 2001). The 15-item scale includes six domains: facial mo-
vement, facial control, oral function, eye comfort, lacrimal control, and social fun-
ction. Both FDI and FaCE questionnaires have been used in several clinical studies 
over the years (Coulson et al. 2004; Lee et al. 2007; Mehta and Hadlock 2008).
Despite many research studies on peripheral facial palsy from Sweden, validated 
questionnaires in Swedish regarding quality-of-life aspects in peripheral facial pal-
sy are still lacking. Using these quality-of-life questionnaires in a language other 
than English requires a rigorous translation and revalidation in the new language 
(Guillemin et al. 1993). 
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AIMS OF THE THESIS
The overall aim of the research project was to examine the effect of different ana-
lysis methods on a Bell’s palsy study and to fi nd clinical prognostic parameters to 
detect those patients at risk for suffering sequelae from the disease. An instrument 
in Swedish for subjective measurement of the impact the facial palsy has on pa-
tients’ quality-of-life was also needed.     
Specifi c aims were:
1. To investigate how the choice of analysis method and the defi nition of 
recovery affect recovery rates in a Bell’s palsy study.
2. To assess if early deterioration of Bell’s palsy is a negative prognostic 
factor for facial outcome at 12 months and if prednisolone treatment 
can prevent this early deterioration. 
3. To develop a prognostic model using clinical parameters, including the 
Sunnybrook scale, to fi nd patients with a poor prognosis as early as pos-
sible in the disease.
4. To translate and validate a Swedish version of the FDI and FaCE-scale 
quality-of-life questionnaires in a Swedish cohort of patients with pe-
ripheral facial palsy. 
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MATERIALS AND METHODS
Patients 
Papers I-III 
Data for the fi rst three papers were extracted from the ‘Scandinavian Bell’s palsy 
study’. This controlled trial included patients with acute unilateral peripheral facial 
palsy from 16 public otorhinolaryngological centers in Sweden and Finland. Pa-
tients aged 18 to 75 years with onset of palsy within 72 hours were included from 
May 2001 to September 2006 with fi nal follow-up in September 2007. 
Exclusion criteria were systemic anti-herpetic medication within the previous 2 
weeks, ongoing systemic steroid medication, allergy to anti-herpetic medication, 
pregnancy, breastfeeding, other neurological diseases, signs of Borreliosis, diabe-
tes, badly-controlled hypertension, current or a history of serious heart disease, 
history of renal or hepatic disease, gastric or duodenal ulcer, history of glaucoma, 
acute otitis or history of ipsilateral chronic otitis, psychiatric disease, or any other 
condition that risked being infl uenced by the study medication or that might have 
affected completion of the study.
In total, 839 of the 1,953 screened patients met the inclusion criteria and were 
randomized into four treatment arms. Ten patients did not take the intended study 
drug and were excluded. Consequently, 829 patients (341 women, 488 men) were 
included in the modifi ed intention-to-treat (ITT) analysis. Baseline assessment was 
performed before treatment start and included otorhinolaryngological examina-
tion, grading of facial function, measurement of ipsilateral pain, documentation of 
concurrent medication, and serum analysis for antibodies to Borrelia burgdorferi. 
Baseline characteristics of the four treatment groups were similar with regard to 
median age, gender, side of palsy, time from onset of palsy to treatment start, and 
median scores of facial function. Patients were randomly assigned to one of four 
treatment groups; placebo plus placebo, prednisolone plus placebo, valacyclovir 
plus placebo, or prednisolone plus valacyclovir within 72 hours after onset of palsy. 
Of these, 206 received placebo plus placebo, 210 prednisolone plus placebo, 207 
valacyclovir plus placebo, and 206 prednisolone plus valacyclovir. Study design 
was factorial with four analysis groups; 416 of the patients were given prednisolone 
whereas 413 were not. Similarly, 413 received valacyclovir and 416 did not. 
Paper IV
Swedish versions of the FDI and FaCE-scale were tested on 93 consecutive patients 
examined between May 2011 and June 2012. The study was performed at two diffe-
rent Otorhinolaryngology centers; the Karolinska University Hospital in Stockholm 
and Uppsala University Hospital in Uppsala, Sweden. 
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Inclusion criteria were age 18 or older and a history of peripheral facial nerve palsy 
of more than 4 months. Patients were excluded if they were non-Swedish speaking, 
required assistance to complete the form, or had primary signs of facial dysfunction 
other than peripheral facial nerve palsy. They were also excluded if cancer in the 
head and neck region was the cause of palsy, since head and neck cancer and its tre-
atment were assumed to cause a reduction in the patient’s quality-of-life indepen-
dently of the facial palsy. Patients with other serious illnesses (severe heart failure, 
spread malignancies and diseases causing severe chronic pain), which could also be 
expected to reduce their overall quality-of-life, were similarly excluded. Vestibular 
schwannoma patients with facial palsy were included if they did not have serious 
balance or vertigo problems.
Methods 
Papers I-III
The included 829 patients were randomly assigned to four treatment arms. Pred-
nisolone (5 mg tablets or its placebo) was given at 60 mg daily for fi ve days, then 
tapering 10 mg per day with a total treatment time of 10 days. Valacyclovir (or its 
placebo) was given as two 500 mg tablets three times daily for 7 days. 
Follow-up visits were scheduled for day 11 to 17 and at 1, 2, 3, 6, and 12 months. If 
recovery was complete (Sunnybrook score =100) at 2 or 3 months, the next follow-
up was at the fi nal 12-month visit. At the fi nal 12-month visit, 743 patients of the 
included 829 were examined (90%). 
Sunnybrook and House-Brackmann facial grading scales were used to assess the 
facial function at all visits. The Sunnybrook scale was used as the main grading 
system to evaluate facial function in the studies. 
Paper IV
Translation process
Translation was performed according to internationally accepted guidelines and 
with permission from the American original authors. English versions of the FDI 
and FaCE-scale were translated independently by two professional otolaryngolo-
gists with excellent knowledge of English but with Swedish as their native langu-
age. A bicultural expert compared the two translated scales and a consensus version 
was obtained. The Swedish version was then separately translated back into English 
by two native English-speaking medical physicians with excellent knowledge of 
Swedish. A professional medical translator then compared the original English ver-
sion with the back-translations. This translator found no conceptual differences in 
the back-translations compared with the original version and the Swedish versions 
of the FDI and FaCE-scale were thus approved in format and content. 
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Pilot study
The Swedish versions of both questionnaires were tested in a pilot study on fi ve 
professional physicians with knowledge of peripheral facial palsy and fi ve patients 
with the same characteristics as the intended study population. Professionals and 
patients completed the questionnaires in the presence of the main author, who ob-
served whether or not they had problems reading or responding to the items. The 
main author then asked questions about the measure’s relevance as well as ease 
of understanding and completion. This testing allowed for corrections in the fi nal 
layout of the questionnaires that made it easier for the patients and doctors to read, 
understand and answer. 
Validation process
Clinical information (etiology of the palsy, duration, co-morbidity, therapy recei-
ved) was collected from the patient or from the patient’s medical records. All sub-
jects’ facial function was graded with House-Brackmann facial grading scale and 
Sunnybrook facial grading scales. 
Patients agreeing to participate fi lled in the FaCE-scale, the FDI and the Medical 
outcomes Study Short Form 36 Item Questionnaire (SF-36) during the clinical vi-
sits. For the retest, the FDI and the FaCE-scale were sent home to the patients two 
weeks later, who then returned them by mail to the examining physician. No treat-
ment for their palsy was given to the study patients during this two-week interim 
period.
Statistical Analysis
Paper I
Facial function recovery rates were assessed with four different analysis methods 
used in similar Bell’s palsy studies (Hato et al. 2003; Kawaguchi et al. 2007; Sul-
livan et al. 2007):  
1. Last observation carried forward, Sunnybrook = 100.
 Recovery defi ned as Sunnybrook score of 100 at 12 months based on the 
intention-to-treat principle and last-observation-carried-forward method 
(n = 829). 
2. Last observation carried forward, House-Brackmann = I.
 Recovery defi ned as House-Brackmann grade I at 12 months based on the 
intention-to-treat principle and last-observation-carried-forward method 
(n = 829). 
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3. Complete-case analysis, House-Brackmann = I.
 Recovery defi ned as House-Brackmann grade I in patients followed until re-
covery plus those remaining at the 12-month follow-up (n = 782) (47 patients 
were lost to follow-up before recovery and excluded). 
4. Complete-case analysis, House-Brackmann ≤ II 
 Recovery defi ned as House-Brackmann ≤ grade II in patients followed until 
recovery plus those remaining at the 12-month follow-up (n = 797) (32 pa-
tients were lost to follow-up before recovery and were excluded). 
Fisher’s exact test was used to compare categorical values. Results are given with 
continuous variables as median values with interquartile range (IQR; 25th–75th 
percentiles) and dichotomous data as proportions with 95% confi dence interval. All 
computations were carried out using SAS software version 9.1 (SAS Institute Inc., 
Cary, NC) and R version 2.4.1 (The R Foundation for Statistical Computing).
Paper II
To identify patients with early deterioration of palsy, deterioration from baseline to 
the fi rst follow-up at days 11 to 17 was registered by Sunnybrook facial grading and 
House-Brackmann grading scores. 
Outcome of palsy at 12 months in patients exhibiting deterioration from baseline to 
the fi rst follow-up visit was compared with subjects whose palsy did not deteriorate 
during this time interval. 
The effect of prednisolone on deterioration of palsy from baseline to fi rst follow-up 
was evaluated with the Sunnybrook grading system by comparing the number of 
patients deteriorating during this interval in subjects receiving prednisolone and in 
those not given the drug. The effect of the drug compared with no treatment on the 
outcome of palsy at 12 months in patients with early deterioration was also assessed 
with the Sunnybrook scaling system. 
Data are presented as median values and interquartile range (IQR; 25th-75th per-
centile). Missing data for patients were handled using the last-observation-carried-
forward (LOCF) method where missing values (facial gradings) were replaced with 
the last available observation for each patient. 
Because the data set was not normally distributed, comparison analyses were perfor-
med using non-parametric methods. The Kruskal-Wallis test was used to compare 
median facial grading values between the deteriorating and the non-deteriorating 
groups. The χ2 (chi-2) test was used to compare proportions of complete recovery. 
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The Kaplan-Meier method was used to estimate survival curves, and the log-rank 
test was used to compare survival distribution of the samples. P < 0.05 was consi-
dered statistically signifi cant. STATA software (version 9; StataCorp LP, College 
Station, TX, USA) was used for all statistical analyses.
Paper III
Prediction model
To develop and validate a clinical prognostic mathematical model, the data set that 
included 829 patients was randomly divided into a training data set comprising 500 
patients (60%) and a validation data set of 329 patients (40%). 
Univariate and multivariate logistic regression analyses with facial function at 12 
months as main outcome were performed using the training data set (n = 500). Po-
tential prognostic factors of outcome were fi rst analyzed by univariate logistic reg-
ression analysis that included patient characteristics at baseline: treatment (predni-
solone or no prednisolone), gender, time from onset to inclusion, age, side of palsy, 
and pain. Statistically signifi cant predictors for non-recovery were then analyzed 
for their independent predictive values using multivariate logistic regression.
Data from days 11 to 17 that included Sunnybrook scores, pain, deterioration from 
baseline to days 11 to 17, and previously mentioned baseline variables were then 
tested in a multivariate model. Finally, a third multivariate model was constructed. 
This included the variables described for the baseline, days 11 to 17 models, and 
Sunnybrook scores at 1 month.
Missing values were replaced with the LOCF method. In addition to LOCF, data 
obtained by the complete-case analysis method (743 patients) were also analyzed in 
all models. The logistic regression models obtained with the training data set were 
also tested on the validation data set (n = 329).
ROC and AUC
To evaluate the diagnostic performance of the logistic regression models, receiver 
operating characteristic (ROC) curves were constructed to discriminate between 
patients with Sunnybrook scores ≥70 and Sunnybrook scores <70 (non-recovery) at 
12 months. ROC analysis curves show the relationship between sensitivity on the 
y-axis and specifi city on the x-axis for different cut-off levels of test positivity. The 
area under the ROC curve (AUC) provides a measure of the overall discriminative 
power of a model. Values can range from 0.5 (no predictive power, expected by 
chance alone) to 1 (perfect prediction).
Results are presented with numbers of observations, odds ratios with 95% confi den-
ce intervals (CI), AUC (95% CI), sensitivity, and specifi city. P values ≤0.05 were 
35
considered signifi cant. Statistical analyses were carried out using the SAS version 
9.2 statistical program (SAS Institute, Cary, NC).
Paper IV
Descriptive statistics are given as number, mean values with standard deviation, 
median with minimum to maximum values, or valid percentage. 
To estimate the internal consistency of the FDI and FaCE-scale when examining all 
the items and the items in each domain, Cronbach’s α coeffi cient was calculated. In-
ternal consistency is considered satisfactory if Cronbach’s α exceeds 0.70, although 
≥0.80 is recommended. Test-retest reliability was calculated through the intraclass 
correlation coeffi cient (ICC) by repeated FDI and FaCE-scale scoring (by test and 
retest) with intervals of 2 weeks.
Cross-sectional validity was tested with Spearman’s rho statistics by comparing 
FDI and FaCE-scale scores to House-Brackmann and Sunnybrook grading scores. 
Construct validity was assessed by creating subscale matrices for the FDI domain 
and FaCE-scale domain as well as total scores to compare with related domains in 
SF-36.  
SF-36 results were calculated using Quality Metric Health Outcomes™ scoring 
software 4.0. Statistical calculations were made in STATA® version 10 (StataCorp 
LP, USA), Statistica 10.0 (Stat Soft Inc Tulsa OK, USA) and IBM SPSS Statistics 
19 (IBM Inc USA). A p-value less than 0.05 was regarded statistically signifi cant. 
RESULTS
Recovery rates (Paper I)
Of the 829 included patients, 341 (41%) were women, and the median age was 40 
years (IQR 31–54). The baseline median Sunnybrook and House-Brackmann sco-
res (for the 829 patients in the intention-to-treat analysis) were 39 (IQR 23–54) and 
4 (IQR 3–5) respectively.
With recovery defi ned as Sunnybrook scale score 100, analysis of the 829 patients 
based on the intention-to-treat principle and last-observation-carried-forward met-
hod showed that 300 of the 416 patients (72%) in the prednisolone group had reco-
vered at 12 months, compared with 237 of 413 patients (57%) who did not receive 
prednisolone (p < 0.0001; Fig 3). For valacyclovir, the corresponding values at 12 
months were 271 of 413 (66%) for the valacyclovir group and 266 of 416 (64%) in 
the no-valacyclovir group (p = 0.66).
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When House-Brackmann grade I was defi ned as recovery, recovery rates at 12 
months in the 829 intention-to-treat patients were 324 of 416 (78%) for those re-
ceiving prednisolone and 266 of 413 (64%) for patients not receiving prednisolone 
(p < 0.0001; Fig. 3). In the valacyclovir group, 297 of 413 (72%) recovered, whereas 
in patients not treated with valacyclovir this fi gure was 293 of 416 (70%) (p = 0.65).
With recovery defi ned as House-Brackmann grade I in patients followed until re-
covery (39 patients had House-Brackmann grade I before 12 months) plus the re-
maining patients with a 12-month follow-up (n = 782), 335 of 389 patients (86%) in 
the prednisolone group had recovered compared with 277 of 393 (70%) in the no-
prednisolone group (p < 0.0001; Fig. 3). The corresponding rates for valacyclovir/
no-valacyclovir groups were 307 of 386 (80%) and 305 of 396 (77%), respectively 
(p = 0.44).
When defi nition of recovery was House-Brackmann I or II in patients followed 
until recovery, plus the remaining patients with a 12-month follow-up (n = 797), 
recovery rates were 380 of 396 (96%) in prednisolone-treated patients and 353 of 
401 (88%) in those not treated with prednisolone (p < 0.0001; Fig. 3). The cor-
responding recovery in the valacyclovir group was 363 of 393 (92%) and in the 
no-valacyclovir group, 370 of 404 (92%) (p = 0.70).
 
Figure 3. Recovery rates in Bell’s palsy patients receiving prednisolone  and not receiving 
prednisolone. Last-observation-carried-forward (LOCF)  method with recovery defi ned as 
Sunnybrook scale score of 100 and House-Brackmann grade I, and complete-case analysis 
method with recovery defi ned as House-Brackmann grade I and ≤ grade II, respectively.
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Early deterioration (Paper II)
Early deterioration of palsy and outcome at 12 months
In 236 (28%) of the 829 patients, palsy deteriorated from baseline to the fi rst fol-
low-up at days 11 to 17. Deterioration was indicated by a drop of ≥30 Sunnybrook 
scores in 34 patients (4%), a drop of 20 to 29 scores in 44 patients (5%), 5 to 19 
scores in 112 patients (14%), and less than 5 in 46 (6%) of the 829 patients. Median 
time for inclusion of the 236 patients with deterioration from baseline to days 11 
to 17 was 24 hours (IQR, 16.5-36 h) compared with 32 hours (IQR, 24-48 h) in the 
593 patients whose condition did not initially deteriorate.
The proportion of patients with complete recovery at 12 months was 106 (45%) 
of 236 subjects whose palsy deteriorated from baseline to days 11 to 17 compared 
with 433 (73%) of 593 patients with no initial deterioration (p < 0.0001), Table IV. 
TABLE IV. Number of Bell’s palsy patients with early deterioration or no early deteriora-
tion. Values are Sunnybrook scores at 12 months and the number of patients (%) with com-
plete recovery at 12 months. Total number is 829 patients.
 Early deterioration No early deterioration p
Sunnybrook n=236 n=593 
Score at 12 months, median 
(IQR) 96 (72-100) 100 (99-100) <0.0001
Complete recovery 
(Sunnybrook =100), n (%) 106 (45) 433 (73) <0.0001
In the 176 patients included between 49 and 72 hours (‘late inclusion’), the condi-
tions of 29 (16%) deteriorated from baseline to days 11 to 17 compared with those 
of 147 patients (84%) that did not deteriorate. The proportion of patients with com-
plete recovery among the ‘late included’ whose conditions deteriorated between 
baseline and days 11 to 17 was 15 (52%) of 29 compared with 112 (76%) of 147 in 
late included patients with no initial deterioration (p = 0.007).
Effect of Prednisolone on Early Deterioration and Outcome at 12 months
As shown in Table V, 105 patients with initial deterioration of palsy had been ran-
domized to prednisolone, whereas 131 patients with initial deterioration did not 
receive prednisolone. Baseline Sunnybrook scorings were similar in the 2 groups.
The number of patients with complete recovery at 12 months was 64 (62%) of the 
105 patients in the prednisolone group compared with 41 (31%) of the 131 patients 
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in the non-prednisolone group (p < 0.0001). Figure 4 shows that early prednisolone 
treatment gave a signifi cantly higher recovery rate among the patients with early 
deterioration (p = 0.001).
Among the 593 patients whose condition did not deteriorate between baseline and 
days 11 to 17, 311 (52%) were randomized to prednisolone and 282 (48%) received 
no prednisolone. At 12 months, 236 (76%) of the patients treated with prednisolone 
and with no initial deterioration showed complete recovery compared with 196 
(70%) of 282 patients with no initial deterioration and who did not receive predni-
solone (p = 0.08; Table V and Fig. 4).
TABLE V. Number of Bell’s palsy patients with early deterioration or no early deterioration and 
treated or not treated with prednisolone. Complete recovery defi ned as Sunnybrook =100.
 Early deterioration  No early deterioration 
 Prednisolone No prednisolone p Prednisolone No prednisolone p
Sunnybrook n=105 n=131  n=311 n=282 
Score at baseline, 
median (IQR) 45 (29-62) 43 (29-58) 0.5 35 (22-51) 37 (19-51) 0.94
Score at 12 months, 
median (IQR) 100 (88-100) 88 (62-100) 0.0001 100 (100-100) 100 (96-100) 0.024
Complete recovery 
n (%) 64 (62) 41 (31) 0.0001 236 (76) 196 (70) 0.081
Figure 4. Kaplan-Meier estimates of patients who made a complete recovery (Sunny-
brook=100). Curves represent patients with early deterioration or no early deterioration and 
treated or not treated with prednisolone.
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Sunnybrook grading at 1 month (Paper III)
Among the seven baseline variables analyzed in the univariate regression analysis, 
treatment (prednisolone or no prednisolone) (p = 0.0005), age (p = 0.04) and Sun-
nybrook score at baseline (p = 0.0002) were statistically signifi cant prognostic fac-
tors for non-recovery. Gender, time from onset of palsy to treatment start, side of 
palsy, and pain at baseline were not signifi cantly correlated with non-recovery.
In the multivariate regression analysis of baseline data: treatment, age, and Sun-
nybrook score at baseline were independent signifi cant predictive factors and were 
used to create the baseline model. In the multivariate analysis of data obtained from 
days 11 to 17, the variables treatment and age lost their predictive ability when ana-
lyzed together with Sunnybrook score at days 11 to 17. Sunnybrook score at days 
11 to 17 was the only variable that was a signifi cant predictive factor (odds ratio 
0.94, 95% CI 0.92-0.96). Multivariate analysis at 1 month also showed the Sunny-
brook score as the only signifi cant factor for non-recovery (odds ratio 0.92, 95% CI 
0.91-0.95). Sunnybrook scores at these time points during recovery were therefore 
used to develop the days 11 to 17 and 1-month models for clinical practice.
Figure 5 shows the ROC curve for the 1-month model for the training and validation 
data sets. The AUC value for non-recovery in the training data set (n = 500) was 
0.74 for the baseline model and 0.83 for the days 11 to 17-model. The correspon-
ding value at 1 month was excellent with AUC 0.94 (sensitivity 0.91, specifi city 
0.85). Validation of the models in the independent validation data set (n = 329) sho-
wed good calibration and discriminative ability for predicting non-recovery (AUC 
0.74 at baseline, 0.87 at days 11 to 17, and 0.94 at 1 month).
The predicted probability for a Sunnybrook score <70 (non-recovery) at 12 months 
was also calculated for the total data set (for patients receiving prednisolone or no 
prednisolone) using the presented 1-month model. As shown in Figure 6, the risk 
for non-recovery predicted at 1 month differs greatly depending on the Sunnybrook 
score at that time point, both in patients treated and not treated with prednisolone. 
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Figure 5. Receiver operating characteristics for Sunnybrook scores at 1 month for the 
training and the validation set. AUC and CI are shown for both sets. 
Figure 6.  Predicted probabilities for patients with non-recovery defi ned as Sunnybrook <70 
at 12 months according to the 1-month Sunnybrook score. The predicted fraction of patients 
with non-recovery at 12 months treated with prednisolone (full line) or not treated with pred-
nisolone (dashed line) on the basis of Sunnybrook score at 1 month is shown.
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Validation of the FDI and FaCE-scale (Paper IV)
A total of 93 patients were included in the study. Forty-nine (53%) were women and 
44 men (47%). The mean age was 56.9 years (range 26-89 years, median 59). The 
mean duration of palsy was 51.9 months with median duration 22 months (range 
4-696 months). The majority of patients (78.5%) were diagnosed with Bell’s palsy. 
The mean Sunnybrook total score was 62.7 with a median of 65.0 (range 1-100). 
Corresponding scores for House-Brackmann were 3.1 (mean), 3.0 (median) and 1-6 
(range). (One patient had recovered objectively with a Sunnybrook score of 100 
and a House-Brackmann score of 1, but still experienced subjective sequelae and 
was therefore included).
The internal consistency of the FDI and FaCE-scale was tested by Cronbach’s α, 
as shown in Table VI. For the FDI domains, Cronbach’s α results were excellent, 
with scores ranging from 0.82 to 0.87. For the FaCE-scale, Cronbach’s α scores for 
Domains and Total scores were also excellent; 0.76 to 0.92. 
Table VI. Internal consistency reliability (Cronbach’s α) and test-retest reliability (intraclass cor-
relations coeffi cient, ICC and 95% CI=confi dence interval) for FDI domains, FaCE-scale domains 
and total scores.
 Internal consistency Test-retest
 Cronbach’s α   ICC 95% CI
FDI Test Retest  
Physical function 0.87 0.86 0.93 0.90–0.96
Social/well-being 
function 0.82 0.80 0.91 0.86–0.94
FaCE-scale    
Social function 0.89 0.91 0.93 0.90–0.96
Total  0.92 0.92 0.97 0.96–0.98
A plot of the patients’ test and retest total scores for the FaCE-scale is shown in 
Figure 7. The degree of agreement was similar when using the test and retest sco-
res from FDI domains physical function and social/well-being function (data not 
shown). The intraclass correlation coeffi cient (ICC) was used as a measure of relia-
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bility. Retest forms were returned by 88 patients (94.6 %). The FDI scores showed 
excellent reliability with ICC results of 0.93 for physical function and 0.91 for 
social/well-being function. ICC results for the FaCE-scale were also excellent; ICC 
ranged from 0.83 to 0.97 (Table VI).
Cross-sectional validity was tested by comparing FDI and FaCE-scale scores (do-
main and total) with Sunnybrook and House-Brackmann scores. Positive correla-
tion was found between the FDI/FaCE-scale scores (Figure 8) and Sunnybrook 
grading, whereas a negative correlation was found between FDI/FaCE-scale and 
House-Brackmann scores. This latter fi nding was expected due to the House-Brack-
mann scale design.
In FaCE-scale, facial movement score showed best correlation with House-Brack-
mann and Sunnybrook scores (-0.81 and 0.85), but oral function and social function 
scores also correlated well. FDI showed good correlation with House-Brackmann 
and Sunnybrook scores in physical function (-0.61 and 0.63), but lower correlation 
with the social/well-being function (-0.38 and 0.40). 
Figure 7. FaCE scale: plot of the patients’ test and retest total scores. 
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DISCUSSION
The disfi guring facial expressions associated with Bell’s palsy can cause signifi -
cant functional, aesthetic, and psychological disturbances to the patient (Yeo et al. 
2007). The terms used to describe satisfactory and unsatisfactory recovery from 
the disease are often poorly defi ned and the reported studies have important met-
hodological differences (Dumitru et al. 1988). The fi ndings in this work show that 
caution must be exercised when interpreting clinical results in Bell’s palsy studies 
reported in the literature. 
The possible sequelae from which Bell’s palsy patients might suffer can be a hin-
drance to an active social life and most patients and their caregivers thus worry 
about the prognosis. An accurate prognosis of the peripheral facial palsy is there-
fore useful for counseling these patients and guiding further treatment. In this work, 
deterioration between baseline and days 11-17 as well as facial function at 1 month 
after onset measured with the Sunnybrook facial grading scale were shown to be of 
prognostic value for the outcome of Bell’s palsy.  
Figure 8. Plot of the patients’ total FaCE-scale scores and Sunnybrook facial grading 
scores.  
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Only through patient-reported outcome instruments can we truly evaluate the suc-
cess of surgical and non-surgical interventions in patients with peripheral facial 
palsy (Ho et al. 2012). To date, instruments in Swedish for measuring quality-of-life 
aspects in this patient group have been lacking. Therefore, two validated patient-
reported outcome instruments for measuring quality-of-life and patient satisfaction 
in peripheral facial palsy have been translated to Swedish and validated.
Why differences in reported recovery rates?
Earlier Bell’s palsy trials have reported varying rates of facial recovery in both 
treated and untreated patients. However, the studies have several methodological 
differences that make comparing results diffi cult. 
This thesis highlights the impact of different statistical analysis methods on calcula-
ted recovery rates in a Bell’s palsy study. The choice of method substantially infl u-
ences the rate of recovery, which varies from 72% to 96% in patients treated with 
prednisolone and from 66% to 92% in patients receiving valacyclovir. A variety of 
factors can affect recovery rates.
Reasons for different outcomes
Inclusion and exclusion criteria in a study determine which patients may be eva-
luated and that might infl uence the severity of palsy at baseline. This will affect the 
prognosis of the palsy (Gilden and Tyler 2007) and thereby also recovery rates. 
The method used to assess facial function is another factor that impinges on re-
covery rates (Hato et al. 2008). Grading facial function from photos (Sullivan et 
al. 2007; Hato et al. 2008) or videos has a lower sensitivity for minor sequelae and 
most probably results in higher recovery rates compared with live grading. 
The grading system used to measure facial function can also impact the outcome. 
Recovery rates were shown to be lower when using the Sunnybrook scale compa-
red to the House-Brackmann scale (72% and 78% respectively in groups treated 
with prednisolone and 57% and 64% in the groups not treated with prednisolone). 
This could be caused by the fact that the regional-weighted Sunnybrook scale suc-
ceeds in reporting results in a more continuous manner and with a wider response 
range than House-Brackmann grading scale (Ross et al. 1996). The gross House-
Brackmann scale is the most widely used scale (Coulson et al. 2005) and has been 
shown to be easy to use, but it displays only a moderate degree of inter-observer 
reliability and fair sensitivity (Chee and Nedzelski 2000). A system with only 6 
different categories does not allow documenting minor changes during a short time 
period, neither as deterioration nor improvement in function (Linder et al. 2010). 
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Investigators have therefore advocated that the Sunnybrook grading scale should be 
applied whenever accurate and precise documentation of facial function is required, 
both in patient counseling and in research (Chee and Nedzelski 2000). 
Follow-up times differ in the literature and can presumably infl uence reported out-
come. In studies, patients with Bell’s palsy were followed at 3 months (Gavilan et 
al. 1988), 6 months (Ikeda et al. 2005), 9 months (Sullivan et al. 2007) or 1 year 
(Smith et al. 1988; Engstrom et al. 2008). It has been shown that no great improve-
ment can be expected more than 1 year after onset of Bell’s palsy (Mantsopoulos et 
al. 2011), but 12 months have been estimated to be required as follow-up period to 
achieve a steady state in the facial muscles (Peitersen 2002). 
Missing data and dropouts in a clinical trial can be dealt with by several different 
methods, but none is fully adequate (Streiner 2002; Lane 2008). In the Scandi-
navian Bell’s palsy trial, the intention-to-treat principle was applied and the last-
observation-carried-forward method used for missing data (Engstrom et al. 2008). 
The rationale behind this approach is that it is conservative; it operates against the 
hypothesis that people will improve over time, and thus under-estimates rather than 
over-estimates the degree of improvement (Streiner 2002; Lane 2008). Statisticians 
have, however, warned that imputing missing values with last observation carried 
forward can introduce bias (Lane 2008; Simpson et al. 2008).
In contrast to last-observation-carried-forward, the complete-case analysis method 
excludes dropout patients and only includes patients with complete data. The reco-
very rate (with recovery defi ned as House-Brackmann grade I) in the prednisolone 
group was 86% with complete-case analysis and 78% with the last-observation-
carried-forward method. Thus, the complete-case analysis resulted in higher re-
covery rates than last-observation-carried-forward. Criticism of the complete-case 
analysis method is that it reduces the sample size and the power of the study. It may 
also produce biased results unless data are missing completely at random (Fielding 
et al. 2008). 
Prognostic factors
The work in this thesis fi rst focused on the prognostic value of Sunnybrook scores 
at 3 months after onset of palsy. This time point was previously used at the ENT 
department in Stockholm for assessing the severity of remaining palsy and for se-
lecting patients at risk for sequelae. In the Scandinavian Bell’s palsy trial, 334 ob-
servations were done at 3 months. This ‘3-months-group’ was divided into different 
subgroups according to the severity of the remaining facial palsy using the 3-month 
visit Sunnybrook scores. Scores of the same patients at baseline, 11-17 days, and 
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1-, 2-, 6-, and 12-months visits were checked. These are shown as a graph in Figure 
9. It can be seen that the best two groups start to improve directly with median 
scores at the second visit exceeding baseline scores. All other groups deteriorate 
in median scores from the initial visit to the next, with the worst groups improving 
very slowly. 
 
The fi nding of this drop in initial score in the groups with worst outcome prompted 
us to evaluate what effect this early deterioration has for outcome in Bell’s palsy. 
Early deterioration 
When focusing on different prognostic factors in predicting the outcome of Bell’s 
palsy, data from the Scandinavian Bell’s palsy trial were again used in the assess-
ments. This study dataset is unique due to the magnitude of patients included, a 
follow-up period of 1 year, a low percentage of patients lost to follow-up, and use 
of the sensitive regional and weighted Sunnybrook scale. The study was summa-
rized with a low risk of bias in the Cochrane report by Lockhart et al. (Lockhart et 
al. 2009). All these factors favor usage of the dataset for implementation of clinical 
predictive studies concerning non-recovery from Bell’s palsy. 
Figure 9. Median Sunnybrook scores at different time points after onset of palsy. Pa-
tients are grouped after severity of palsy at 3 months using their Sunnybrook score at 
that time point. n=334.
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Bell’s palsy has a high spontaneous recovery, but up to 30% of patients experience 
sequelae (Peitersen 2002). Since sequelae can be severe, patients are often seriously 
worried about their disease throughout its clinical course, and they expect physici-
ans to be able to predict the outcome of their palsy. 
Early deterioration of Bell’s palsy, defi ned as deterioration in Sunnybrook scores 
from baseline (within 72 h) to days 11 to 17, was found to be a negative prognostic 
factor for complete recovery at 12 months. Early deterioration was demonstrated in 
28% of patients. It may be speculated that this early deterioration was partly due to 
these patients seeking medical care earlier (median of 24 h after onset) than patients 
with no initial deterioration (median of 32 h after onset), resulting in an assessment 
of their facial function being made before the palsy reached its maximum weak-
ness. However, the time for the initial clinical assessment during the fi rst 72 hours 
does not seem to entirely explain the poorer outcome in the deteriorating group; 15 
(52%) of 29 patients with early deterioration and initially examined late (between 
49 and 72 hours after onset of palsy) had similar complete recovery rates to those 
with early deterioration but examined between 0 and 72 hours (106 of 236 patients, 
45%).
Our fi ndings of early deterioration as a negative prognostic factor are in agreement 
with the report by Linder et al. (Linder et al. 2010). They found that in patients 
with an initial drop of facial score plus paralysis (severe palsy), 30% had delayed 
improvement and incomplete recovery. In an earlier study by May et al. (May et al. 
1976), 12 (24%) of 51 Bell’s palsy patients progressed from incomplete to a com-
plete palsy. Both studies used regional grading systems similar to the Sunnybrook 
system used in paper II.
Sunnybrook score at 1 month 
Sunnybrook grading at 1 month showed the ability to accurately predict non-re-
covery at 12 months in Bell’s palsy. The risk of not reaching full recovery (Sun-
nybrook < 70) was evaluated based on age, gender, time to inclusion, prednisolone 
treatment, side of palsy, pain at inclusion and Sunnybrook score at baseline, days 
11-17, and 1 month. A prediction model is presented that identifi es Bell’s palsy 
patients at 1 month with a high risk for non-recovery at 12 months. The accuracy 
of the ROC model was excellent at 1 month (AUC = 0.94) and the main predictor 
for non-recovery was the Sunnybrook score at 1 month. The predictive value of 
Sunnybrook grading at baseline was weaker than at days 11 to 17 and at 1 month, 
which is refl ected by the AUC values for the prediction model (AUC = 0.74 at ba-
seline, 0.83 at days 11 to 17, and 0.94 at 1 month). The improvement in predictive 
capability over time may be explained by the palsy being unstable in its early stage 
and then stabilizing.
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The presented model is validated and simple to use for early identifi cation of pa-
tients with a high risk for poor outcome. It may be used for planning and the need 
for follow-up visits.
Why the necessity to predict outcome early?
It is important to identify patients at risk for suffering sequelae early for several 
reasons. Some of the patients with inadequate improvement of facial function will 
require plastic reconstructive intervention to achieve better facial symmetry (Bul-
strode and Harrison 2005). Today, surgical nerve crossover techniques can be used 
to improve facial function (Rosson and Redett 2008). This surgery is best carried 
out before the muscles on the paralyzed side become atrophied. The time interval 
when surgery needs to be performed is preferably within 9 months after onset of 
palsy (Terzis and Tzafetta 2009). It is therefore important to early predict those pa-
tients who risk suffering sequelae and to identify candidates for surgery. 
Furthermore, patients with Bell’s palsy worry about the risk for permanent facial 
deformity and are eager to determine their chances of recovery. It is important to 
save patients with good prognosis some mental distress whenever possible. In ad-
dition, outpatient clinic resources may be scarce, so unnecessary visits to the doctor 
should be avoided if possible. The presented results show that 1 month after onset 
of palsy is an optimal time point for clinical prediction of non-recovery in Bell’s 
palsy. By examining patients with Bell’s palsy at this time, those at risk of suffering 
sequelae could be identifi ed and clinical resources, e.g. surgery, physical therapy 
and speech therapy, allocated to these patients. 
Prognostic clinical signs and tests in literature
The predictive value of facial function at 1 month is in accordance with the re-
ported fi ndings of Ikeda et al., who found that the House-Brackmann grading at 1 
month had a statistical signifi cance for the prognosis of facial paralysis (Ikeda et al. 
2005). Our fi ndings of the high predictive capacity of Sunnybrook at 1 month are, 
however, in contrast to those of Takemoto and co-workers (Takemoto et al. 2011). 
They reported that Yanagihara grading at baseline as well as the worst grading score 
during recovery are not signifi cant predictable variables. These contradictive re-
sults may be due to the difference in grading systems used (Yanagihara scale is not 
weighted), fewer patients included in their study, the time points for the predictive 
evaluation, and different defi nitions of non-recovery.
In the early acute setting, there are no electrical, radiologic, or clinical tests that 
can accurately predict the fi nal facial outcome for the individual patient (Adour 
et al. 1985; Peitersen 2002; Lee et al. 2006; Yeo et al. 2007; Ushio et al. 2008). It 
is known that ENoG is a useful test to assess the prognosis of Bell’s palsy (Fisch 
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1984). However, test equipment for ENoG is relatively expensive and can be dif-
fi cult to use (Ikeda et al. 2005). Furthermore, the test should not be performed as 
a prognostic indicator until at least 3-14 days after the onset of palsy (Chow et al. 
2002; Kress et al. 2004; Valls-Sole 2007), and it is not always reliable in predicting 
outcome (Qiu et al. 1996; Lee et al. 2006). Moreover, access to this method can be 
very limited and as a result, other clinical factors that can accurately predict prog-
nosis have been sought after.  
Clinical indicators for poor prognosis have been proposed, including severity of 
initial facial palsy, old age, presence of pain, hypertension, and diabetes mellitus 
(Danielides et al. 1996; Peitersen 2002; Ikeda et al. 2005; Hsieh et al. 2009). Howe-
ver, these factors are inconclusive and not powerful enough in the clinical situation. 
Additional clinical prognostic tools are therefore needed (Yeo et al. 2007; Ushio et 
al. 2008; Burmeister et al. 2011). 
Age was not a predicting factor for non-recovery in this work. In other studies, the 
infl uence of age on outcome has been reported to be signifi cant (Adour and Wingerd 
1974; Danielides et al. 1996; Peitersen 2002; Ushio et al. 2008).  With increasing 
age there is an increase in vascular degeneration which leads to a decrease of the 
peripheral blood supply. This has been an argument for possible decrease in facial 
nerve recovery in older patients with Bell’s palsy (Danielides et al. 1996). However, 
several studies show that age was not among the most important variables in pre-
dicting prognosis of Bell’s palsy (Gavilan et al. 1988; Yeo et al. 2007; Takemoto et 
al. 2011). This latter observation is in agreement with the presented results.
The importance of presented results
The impact of study design on recovery rates in Bell’s palsy has recently been deba-
ted (Gilden and Tyler 2007; Davenport et al. 2008; Hato et al. 2008). The presented 
results show that the analysis method and defi nition of recovery used in a Bell’s 
palsy study can substantially affect calculated recovery rates at 12 months. The-
refore, comparison of recovery rates between different studies has to be carefully 
interpreted. If the study design is not taken into account, important methodological 
differences may be overlooked and comparisons between recovery rates in untrea-
ted patients (Peitersen 2002) and patients treated with prednisolone (Sullivan et al. 
2007) may result in erroneous conclusions (Romijn et al. 2008).
Case history, clinical investigations and laboratory tests have to be combined in 
order to estimate outcome correctly (Hyden et al. 1982). The fi nding that early de-
terioration is a risk factor for non-recovery, together with the presented prognostic 
model and 1 month-risk curve, may be an additional tool for identifying patients at 
risk for sequelae and may help clinicians in their work. 
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Corticosteroid treatment
Among patients treated with prednisolone, the number with early deterioration was 
lower compared with patients not given prednisolone. In patients with early deterio-
ration, prednisolone medication compared with no prednisolone resulted in a larger 
proportion with complete recovery at 12 months.
The background for early deterioration is unclear. The pathological process in Bell’s 
palsy is most probably related to an infl ammatory reaction with edema along the 
facial nerve in the fallopian canal. Owing to its anti-infl ammatory effect, steroid 
treatment may reduce this infl ammation and prevent further nerve damage. 
Whether early corticosteroid treatment could prevent deterioration from paresis to 
complete clinical paralysis has so far not been suffi ciently documented (Linder et 
al. 2010), but it seemed prudent to treat patients early to prevent further deteriora-
tion of a palsy to complete paralysis (Linder et al. 2010). Adour et al suggested an 
association between early prednisolone treatment and less severe disease (Adour et 
al. 1996). However, May et al found no benefi cial effect of early steroid treatment 
on disease progression or fi nal outcome (May et al. 1976).
Patients with incomplete acute Bell’s palsy should start to improve their facial fun-
ction early (3-weeks after onset) and are expected to recover completely within 3 
months (Peitersen 2002). Some argue that only patients with severe palsy should 
be prescribed steroid treatment (Sathirapanya and Sathirapanya 2008) since those 
with incomplete palsy are expected to recover without treatment. At the initial visit, 
however, it is not possible to predict if the conditions of these patients are likely 
to deteriorate to a paralysis (severe or complete palsy) (Linder et al. 2010). Pred-
nisolone treatment, when compared with no prednisolone medication, resulted in 
a lower number of patients with early deterioration and a higher proportion with 
complete recovery. The reported high percentage of patients with early deteriora-
tion (May et al. 1976; Linder et al. 2010), plus our fi ndings that prednisolone may 
reduce progression and improve outcome in the deteriorating group, justifi es early 
corticosteroid treatment even in patients with an initially mild Bell’s palsy. 
Peripheral facial palsy and quality-of-life
The face is the primary source of identifi cation for human beings, displaying emo-
tions effectively and enhancing communication between individuals. Patients with 
facial palsy suffer a profound loss because of the impairment of this system (Byrne 
2004). The effect that altered facial motion has on those suffering from facial palsy 
is signifi cant. Depressive symptoms are reported in 65% of those with facial neu-
romotor disorders, an incidence three to fi ve times that of the general population 
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(VanSwearingen et al. 1998). Finding ways to measure the impairment and disa-
bility that the patient with peripheral facial palsy experience is therefore of great 
importance. 
The FDI and FaCE-scale were translated into Swedish and validated in patients 
with peripheral facial palsy. The two questionnaires showed very good psychome-
tric properties with high validity and reliability. No major diffi culties were observed 
in the translation and cultural adaptation of the questionnaires. The instruments 
were easily understood by patients and straightforward to fi ll in. Compliance was 
high and missing response values very low. 
The majority of scales used today are physician-ranking scales used to quantify 
impairments of facial resting posture and movement (Ho et al. 2012). More re-
cently, outcomes have been analyzed with respect to patient satisfaction, functional 
outcome and quality-of-life (Coulson et al. 2004; Ryzenman et al. 2005; Saito and 
Cheung 2010).
The systematic review of Ho et al. identifi ed only three patient-reported outcome 
instruments for quality-of-life that were developed and validated for facial palsy 
patients and in which FDI and FaCE-scale were considered applicable for the gene-
ral facial paralysis population (Ho et al. 2012). In English, both the FDI (VanSwea-
ringen and Brach 1996) and FaCE-scale (Kahn et al. 2001) are proven to be valid 
and reliable specifi c questionnaires. FDI was recently translated into Spanish (Gon-
zalez-Cardero et al. 2012) but FaCE-scale has not been translated and validated in 
other languages. 
Both the translated FDI and FaCE-scale showed very good to excellent internal va-
lidity with Cronbach’s α scores between 0.76 and 0.92 for domain and total score. 
The response rate for the retest was as high as 95% for the patients who responded 
to the second questionnaire. Both questionnaires had good reliability with intra-
class correlation scores ranging from 0.83 to 0.97, and good sensitivity, i.e. the 
ability to discriminate between patients with varying degrees of impairment. Both 
questionnaires also showed good cross-sectional validity with high correlation with 
the House-Brackmann and Sunnybrook facial grading scales. The strong correla-
tion between the FaCE-scale facial movement domain score and House-Brackmann 
(r = -0.81) agrees with the results (r = -0.55 and -0.69) of the original FaCE-scale 
validation performed by Kahn et al. (Kahn et al. 2001).  
Social function domains showed lower correlation values with House-Brackmann 
and Sunnybrook scoring systems than did physical domains. Lower values for soci-
al function domain correlation with House Brackmann were also reported by Kahn 
et al. (Kahn et al. 2001) in the original study.
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Relationship between severity of palsy and subjective distress
Studies have shown that there is no clear relationship between degree of disfi gure-
ment and degree of subjective distress (Bradbury et al. 2006). For example, Cross 
et al. found no association between the severity of facial impairment and the level 
of psychological distress measured in 29 patients experiencing facial paralysis for 
at least one year after acoustic tumor surgery (Cross et al. 2000). In the report by 
Lee et al., social disability measured by the FaCE-scale could not be predicted by 
the severity of facial paralysis in 56 patients with facial weakness after vestibular 
schwannoma surgery (Lee et al. 2007). This illustrates the diffi culty in measuring 
social aspects of the disease with only objective physician-graded instruments. 
The reasons for low correlation between social function and objective physical 
measurements in this work, as in the literature, can be several. Factors that mediate 
individual responses such as personal resilience, strong family and social support, 
and the development of effective coping strategies are some examples. Patients who 
have had their palsy for a longer time can adapt to the handicap and accept their 
situation. Many of the patients included in the present study spontaneously reported 
that they would have answered the social domain questions differently if they had 
been asked the same questions earlier during their disease. Further, patients under-
going vestibular schwannoma surgery are informed about the risk for peripheral 
facial palsy beforehand, and have time to mentally prepare for possible sequelae.
The extent of the psychological problems due to the patients’ facial palsy has pro-
bably not been fully understood by clinicians. Ikeda and colleagues (Ikeda et al. 
2003) evaluated 131 patients with peripheral facial palsy and scored 20-30% of the 
patients ‘cured’ with the Yanagihara and House-Brackmann scales. Yet, the same 
patients experienced the persistence of minor dyskinesia and did not rate them-
selves as cured. It has been suggested that the long-term sequelae of facial nerve 
paralysis has been underestimated by clinicians (Smith et al. 1994). It is therefore 
of great importance that the physician takes the social and psychological aspects of 
the disease in account when handling the patient.
The Swedish versions of the FDI and FaCE-scale questionnaires showed high re-
liability and validity and can be used for clinical studies on patients with peripheral 
facial palsy in Sweden. The inclusion of self-report measures in the assessment 
process, and a focus on issues drawn from these patients’ reports, could be directly 
fed back into clinical treatment strategies. Psychological support is sometimes as-
ked for by patients with peripheral palsy in distress, but many patients included in 
this work revealed that they withheld requests for psychological counseling since 
that option never was presented by the doctor, and also seemed impossible to ask 
for. This should be taken into account when planning future treatment options for 
these patients.
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Limitations
The number of physicians involved in the Scandinavian Bell’s palsy study was 49. 
Early stage assessments were often done by less experienced physicians, although 
help was available from more senior colleagues. To reduce these problems, the Sun-
nybrook scale was used as the main facial grading system. This system has good 
repeatability and has reliable agreement between observers, even with novice users 
(Kanerva et al. 2006). The Scandinavian Bell’s palsy study included 829 patients. 
Of these, 719 had their facial function assessed at 1 month. In our prediction model, 
we used imputed data for missing values (n = 829) in the follow-up visits. To over-
come the possible infl uence of this statistical method, we therefore also analyzed 
data with complete-case analysis (n = 743). The two methods gave similar results.
Facial function was assessed at baseline and at days 11 to 17 in the early stage. 
Daily assessments would have made it possible to study if the difference between 
rapid and slow progression was related to the outcome of palsy. We found no corre-
lation between the severity of early deterioration, measured by progression in Sun-
nybrook grades, and outcome. However, the subgroups studied were comparatively 
small. 
Results are presented with the Sunnybrook facial grading system, but in the Scan-
dinavian Bell’s palsy study, facial function was also assessed by House-Brackmann 
grading. As could be expected (according to earlier argumentation), the number of 
patients with early deterioration was greater with the more sensitive Sunnybrook 
scale compared with the gross House-Brackmann system. Nevertheless, when ana-
lyzed, the overall result for early deterioration and facial grading score at 1 month 
as a signifi cant negative prognostic factor for complete recovery was similar for 
both grading systems.
The quality-of-life questionnaires were not tested for responsiveness to change 
(Heffernan and Jenkinson 2005). Testing patients in the early stage of facial palsy 
and re-examining at different time points during follow-up would allow analysis 
of how the FDI and FaCE-scale’s scores change in relation to changes in House-
Brackmann and Sunnybrook scores over time. This has not previously been tested, 
even in the original English versions, and might therefore be a study for the future. 
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CONCLUSIONS
• Calculated recovery rates at 12 months in a Bell’s palsy study are 
substantially affected by the choice of analysis method and defi nition 
of recovery. 
• Deterioration in facial function in Bell’s palsy from baseline (within 
72 h) to days 11 to 17 is a negative prognostic factor for recovery 
at 12 months. Early prednisolone treatment reduces progression of 
palsy and improves outcome in patients with early deterioration. 
• Sunnybrook grading at 1 month accurately predicts non-recovery 
(defi ned as Sunnybrook < 70) at 12 months in Bell’s palsy. A simple-
to-use risk curve for non-recovery at 12 months that can be used in 
the clinical setting is presented. 
• Swedish versions of the FDI and FaCE-scale questionnaires showed 
high reliability and validity. Both can be applied as useful tools for 
clinical evaluations and future studies in Swedish patients with pe-
ripheral facial palsy. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING
Bells pares defi nieras som ansiktsförlamning av okänd orsak. Sjukdomen drabbar 
ca 25-30 per 100 000 personer och år. Förlamningen debuterar relativt snabbt och 
sjukdomen kännetecknas av svaghet eller total förlamning av muskulaturen som 
sköter mimiken i halva ansiktet. Patienten blir svag i mungipan, får svårt att stänga 
ögat och blir svag i pannan. Många får problem att dricka, äta och prata och vissa 
kan även få påverkad hörsel, smak och känna smärta bakom ena örat. Prognosen är 
oftast mycket god men ca 30 % får kvarstående besvär. Många av dessa mår fysiskt 
och psykiskt väldigt dåligt av sina kvarvarande symtom.
Man har länge letat efter kliniska tecken som kan förutspå vilka som kommer drab-
bas av kvarstående förlamning. Inga studier har dock kunna hitta tillräckligt starka 
faktorer. Studier har även presenterat stora skillnader i utläkningsgrad hos patienter 
trots liknande behandling. Det har inte funnits någon enkät för mätning av sjukdo-
mens påverkan på livskvalitet på svenska.
Målet med avhandlingen
• Att undersöka hur val av design, statistiska analys-metoder och defi nition 
av utläkning kan påverka den framräknade utläkningsgraden i en Bells pa-
res studie.
 
• Att fi nna kliniska faktorer som kan vara till hjälp för att förutspå vilka med 
Bells pares som inte kommer läka ut. 
• Att översätta och validera två amerikanska livskvalitets-enkäter till svens-
ka.
Resultatet av avhandlingsarbetet visar att val av analysmetod och defi nition av ut-
läkning påtagligt påverkar graden av framräknad utläkning av Bells pares. I det 
använda materialet skilde sig utläkningsgraden mellan 72% och 96%. Detta kan 
förklara skillnader i presenterade utläkningsgrader i olika studier med likande be-
handling.  Resultaten visar att försiktighet måste användas vid jämförelse av olika 
studier av Bells pares för att inte felaktiga slutsatser ska dras. 
Försämring av ansiktsfunktionen mellan det akuta besöket och första återbesöket 
(vid 11-17 dagar) är ett prognostiskt dåligt tecken för utläkning. Behandling med 
kortisontabletter inom 72 timmar från förlamningens debut kan bromsa denna ti-
diga försämring och påverka utläkningen positivt. 
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Ansiktsfunktionen vid 1 månad efter insjuknandet mätt med den objektiva Sun-
nybrook-skalan, kan användas för att förutspå risken för att patienten ska drabbas 
av dålig utläkning. En riskkurva baserad på en framtagen prediktionsmodell pre-
senteras. Denna riskkurva kan användas i det kliniska arbetet för att tidigt kunna 
identifi era patienter som löper risk för att få kvarstående besvär. Dessa patienter 
skulle i så fall snabbare kunna få hjälp med åtgärder såsom sjukgymnastik eller 
nerv-kirurgi. 
Två amerikanska livskvalitet-enkäter har översatts till svenska. Dessa är lättanvän-
da och pålitliga. De kan med fördel användas i det dagliga kliniska arbetet och i 
framtida studier på patienter med ansiktsförlamning i Sverige.  
 
57
ACKNOWLEDGEMENTS
The work presented in this thesis has involved a number of people to whom I am 
greatly indebted. My journey in the land of research has been long and winding and 
I wish to express my sincere gratitude to my colleagues, friends and family for their 
help and support during these years. I would never have made it without you all. In 
particular I would like to acknowledge:
My tutor, Professor Malou Hultcrantz. Thank you for encouraging me, for beli-
eving in me and for providing me with the possibilities to perform this work. You 
are a role model in many ways, with your excellent clinical skills, your knowledge 
of science, your enormous scientifi c and clinical network, and your spectacular 
sense of fashion... You rock! 
My co-tutor, Lalle Hammarstedt-Nordenvall. Colleague and friend for many 
years, you are the reason for me doing this. You dragged me to that meeting with 
Birgit Stark and one thing gave another and suddenly I was Mrs. Bell’s palsy re-
search! Thank you for all support, all gossip and all the good laughs. And no, I will 
never go running with you. Stop asking.
My co-author Lars Jonsson for all help. We have spent many hours over Skype 
rewriting and rewriting and rewriting the manuscripts. You taught me that a manus-
cript can always be read through one more time… and I am convinced that your 
meticulousness is the reason why they were all accepted without any problem.
My co-authors Thomas Berg, Mats Engström and Nina Bylund for good team-
work, good ideas and stimulating discussions. 
Nermin Hadziosmanovic for all help with the statistics in papers I-III. It cannot 
have been easy to try to explain to a stupid ENT doctor the true meaning of LOCF, 
ROC, AUC and other impossible abbreviations!
Elisabeth Berg for all the help with the statistics in paper IV. 
The research nurses Samira Nikman, Maria Axelsson, Carina Israelsson and 
Helena Öfverberg for help with gathering patients for paper IV. Your help really 
made things happen with the study! 
Department Professor Lars-Olaf Cardell, and the FoUU committee for creating 
an inspiring academic atmosphere.
58
Agneta Wittlock for administrative assistance and mostly the priceless help with 
the lay-out of this thesis. You are great!
Dr Richard Kuylenstierna, Dr Mats Holmström and Dr Bo Tideholm, former 
and present Heads of Department of Otorhinolaryngology. Thank you for your sup-
port, for providing me time to complete this thesis and for showing genuine interest 
in my work. 
Professor Dan Bagger Sjöbäck, my ex-tutor, for always being very kind to me, 
encouraging me in my work and giving me valuable advice when I have needed it.
Dr Birgit Stark and colleagues at the Department for Reconstructive Plastic Sur-
gery and Dr Bengt Y Nilsson at the Department of Neurophysiology at Karolinska 
University Hospital for good research collaboration. 
My roommates Caroline Gahm, Linda Marklund and Rusana Simonoska; I was 
the only one in the room without a PhD degree, now I’m a full member of the team! 
Thank you for all the laughs and for the extraordinary atmosphere we have in our 
room!
All my colleagues at the ENT Department at Karolinska. Whether you are po-
sitioned up north, down south or to the east: you all make going to work fun and 
interesting!  
Gunnar Björck, my clinical supervisor, for introducing me to the wonderful world 
of Phoniatrics. Thank you for being so supportive in my research, even though I 
think you really just wanted me to get this PhD stuff over with and get down to real 
business! 
My phoniatric colleagues Per-Åke Lindestad, Stellan Hertegård and Riitta 
Möller for being such an inspirational source of knowledge and for always being 
so nice and friendly.
All patients, thank you for taking the time to participate in my studies. Your open-
hearted portrayal of how life with peripheral facial palsy is has taught me much, and 
your stories will stay with me forever. 
59
And to my family and dear friends outside my research and clinical work, 
especially: 
Madoka and Fredrik with family. Madoka, your creativeness, humor and words 
of wisdom (“Elin, you need to understand, men are stupid”) have really given me 
joy and helped me through tough times. I am so grateful for your friendship and I 
look forward to more travels around the world with you and your family. 
Sofi e Paues Göranson: for our friendship that has survived many years of studies 
(well, maybe not so much studies), theater plays, singing, endless parties, work and 
now family life. I feel gratitude for a lot of things and I now hope that your research 
will start to bear fruit!
Richard’s family: Barbro & Kjell, Lars & Anna, Karin & Daniel with Ham-
pus, Frans and Mia: thank you all for support and encouragement. Through hard 
times and good times, through sickness and health, this family sticks together, just 
as it should be! I am so grateful to be privileged with such a lovely family-in-law.
My dear Mother, thank you for EVERYTHING. You taught me the importance of 
perseverance and gave me strength to never give up. And thank you for all help with 
Nils and Matilda, they adore you and I am so grateful that you are there. 
Richard, my love and best friend. You never stop to amaze me, in all possible 
ways. Your humor, good spirit, support and comfort are essential for my life. I hope 
it will continue to be you and me for many, many more years to come. I love you. 
Nils and Matilda, our fantastic children. Putting you into this world has been my 
greatest achievement by far and you fi ll my days with so much joy, laughter, pride 
and true meaning. 
The research conducted for this thesis was supported by grants from Stiftelsen 
ACTA Otolaryngologica, KI funds, CLINTEC and ALF.
 
60
REFERENCES
Adour, K. K. (1991). ”Medical management of idiopathic (Bell’s) palsy.” Otolaryngologic clinics of 
North America 24(3): 663-673.
Adour, K. K. (1994). ”Otological complications of herpes zoster.” Annals of neurology 35 Suppl: 
S62-64.
Adour, K. K., et al. (1975). ”Herpes simplex virus in idiopathic facial paralysis (Bell palsy).” JAMA 
: the journal of the American Medical Association 233(6): 527-530.
Adour, K. K., et al. (1985). ”Facial paralysis and Bell’s palsy: a protocol for differential diagnosis.” 
The American journal of otology Suppl: 68-73.
Adour, K. K., et al. (1996). ”Bell’s palsy treatment with acyclovir and prednisone compared with 
prednisone alone: a double-blind, randomized, controlled trial.” The Annals of otology, rhi-
nology, and laryngology 105(5): 371-378.
Adour, K. K. and J. Wingerd (1974). ”Idiopathic facial paralysis (Bell’s palsy): factors affecting 
severity and outcome in 446 patients.” Neurology 24(12): 1112-1116.
Adour, K. K., et al. (1972). ”Prednisone treatment for idiopathic facial paralysis (Bell’s palsy).” The 
New England journal of medicine 287(25): 1268-1272.
Baricich, A., et al. (2012). ”Peripheral facial nerve palsy: how effective is rehabilitation?” Otology 
& neurotology 33(7): 1118-1126.
Berg, T., et al. (2009). ”The course of pain in Bell’s palsy: treatment with prednisolone and valacy-
clovir.” Otology & neurotology 30(6): 842-846.
Beurskens, C. H. and P. G. Heymans (2004). ”Physiotherapy in patients with facial nerve paresis: 
description of outcomes.” American journal of otolaryngology 25(6): 394-400.
Botman, J. W. and L. B. Jongkees (1955). ”The result of intratemporal treatment of facial palsy.” 
Practica oto-rhino-laryngologica 17(2): 80-100.
Bradbury, E. T., et al. (2006). ”Psychological and social factors in reconstructive surgery for hemi-
facial palsy.” Journal of plastic, reconstructive & aesthetic surgery : JPRAS 59(3): 272-278.
Brandle, P., et al. (1996). ”Correlation of MRI, clinical, and electroneuronographic fi ndings in acute 
facial nerve palsy.” The American journal of otology 17(1): 154-161.
Brugel, F. J., et al. (1993). ”Reliability of diagnostic procedures in facial paralysis with special 
reference to magnetic resonance tomography.” Laryngo- rhino- otologie 72(10): 506-510.
Bulstrode, N. W. and D. H. Harrison (2005). ”The phenomenon of the late recovered Bell’s palsy: 
treatment options to improve facial symmetry.” Plastic and reconstructive surgery 115(6): 
1466-1471.
Burgess, L. P., et al. (1984). ”Bell’s palsy: the steroid controversy revisited.” The Laryngoscope 
94(11 Pt 1): 1472-1476.
Burgess, R. C., et al. (1994). ”Polymerase chain reaction amplifi cation of herpes simplex viral DNA 
from the geniculate ganglion of a patient with Bell’s palsy.” The Annals of otology, rhino-
logy, and laryngology 103(10): 775-779.
Burmeister, H. P., et al. (2011). ”Evaluation of the early phase of Bell’s palsy using 3 T MRI.” Eu-
ropean archives of oto-rhino-laryngology 268(10): 1493-1500.
Burres, S. and U. Fisch (1986). ”The comparison of facial grading systems.” Archives of otolaryng-
ology--head & neck surgery 112(7): 755-758.
Byrne, P. J. (2004). ”Importance of facial expression in facial nerve rehabilitation.” Current opinion 
in otolaryngology & head and neck surgery 12(4): 332-335.
Chee, G. H. and J. M. Nedzelski (2000). ”Facial nerve grading systems.” Facial plastic surgery : 
FPS 16(4): 315-324.
Chow, L. C., et al. (2002). ”Use of electroneurography as a prognostic indicator of Bell’s palsy in 
Chinese patients.” Otology & neurotology 23(4): 598-601.
61
Coulson, S. E., et al. (2005). ”Reliability of the ”Sydney,” ”Sunnybrook,” and ”House Brackmann” 
facial grading systems to assess voluntary movement and synkinesis after facial nerve para-
lysis.” Otolaryngology--head and neck surgery 132(4): 543-549.
Coulson, S. E., et al. (2004). ”Expression of emotion and quality of life after facial nerve paralysis.” 
Otology & neurotology 25(6): 1014-1019.
Cross, T., et al. (2000). ”Impact of facial paralysis on patients with acoustic neuroma.” The Laryng-
oscope 110(9): 1539-1542.
Croxson, G., et al. (1990). ”Grading facial nerve function: House-Brackmann versus Burres-Fisch 
methods.” The American journal of otology 11(4): 240-246.
Danielides, V., et al. (1996). ”A comparison of electroneuronography with facial nerve latency tes-
ting for prognostic accuracy in patients with Bell’s palsy.” European archives of oto-rhino-
laryngology 253(1-2): 35-38.
Davenport, R. J., et al. (2008). ”Treatment for Bell’s palsy.” Lancet 372(9645): 1219-1220; author 
reply 1220-1211.
Duel, A. B. (1934). ”The Operative Treatment of Facial Palsy.” British medical journal 2(3857): 
1027-1058 1021.
Dumitru, D., et al. (1988). ”Electrophysiologic evaluation of the facial nerve in Bell’s palsy. A re-
view.” American journal of physical medicine & rehabilitation / Association of Academic 
Physiatrists 67(4): 137-144.
Engstrom, M., et al. (1997). ”Serial gadolinium-enhanced magnetic resonance imaging and as-
sessment of facial nerve function in Bell’s palsy.” Otolaryngology--head and neck surgery 
117(5): 559-566.
Engstrom, M., et al. (2008). ”Prednisolone and valaciclovir in Bell’s palsy: a randomised, double-
blind, placebo-controlled, multicentre trial.” Lancet neurology 7(11): 993-1000.
Esslen, E. (1977). ”The acute facial palsies: investigations on the localization and pathogenesis of 
meato-labyrinthine facial palsies.” Schriftenreihe Neurologie 18: 1-164.
Fielding, S., et al. (2008). ”A review of RCTs in four medical journals to assess the use of imputation 
to overcome missing data in quality of life outcomes.” Trials 9: 51.
Fisch, U. (1984). ”Prognostic value of electrical tests in acute facial paralysis.” The American jour-
nal of otology 5(6): 494-498.
Fisch, U. and E. Esslen (1972). ”Total intratemporal exposure of the facial nerve. Pathologic fi n-
dings in Bell’s palsy.” Archives of otolaryngology 95(4): 335-341.
Fisch, U. and H. Felix (1983). ”On the pathogenesis of Bell’s palsy.” Acta oto-laryngologica 95(5-
6): 532-538.
Furuta, Y., et al. (1998). ”Reactivation of herpes simplex virus type 1 in patients with Bell’s palsy.” 
Journal of medical virology 54(3): 162-166.
Furuta, Y., et al. (2000). ”High prevalence of varicella-zoster virus reactivation in herpes simplex 
virus-seronegative patients with acute peripheral facial palsy.” Clinical infectious diseases : 
an offi cial publication of the Infectious Diseases Society of America 30(3): 529-533.
Gantz, B. J., et al. (1984). ”Electroneurographic evaluation of the facial nerve. Method and technical 
problems.” The Annals of otology, rhinology, and laryngology 93(4 Pt 1): 394-398.
Gavilan, C., et al. (1988). ”Discriminant analysis in predicting prognosis of Bell’s palsy.” Acta oto-
laryngologica 106(3-4): 276-280.
Gilchrist, J. M. (2009). ”Seventh cranial neuropathy.” Seminars in neurology 29(1): 5-13.
Gilden, D. H. and K. L. Tyler (2007). ”Bell’s palsy--is glucocorticoid treatment enough?” The New 
England journal of medicine 357(16): 1653-1655.
62
Gonzalez-Cardero, E., et al. (2012). ”Facial disability index (FDI): Adaptation to Spanish, reliability 
and validity.” Medicina oral, patologia oral y cirugia bucal.
Guillemin, F., et al. (1993). ”Cross-cultural adaptation of health-related quality of life measures: 
literature review and proposed guidelines.” Journal of clinical epidemiology 46(12): 1417-
1432.
Hato, N., et al. (2003). ”Effi cacy of early treatment of Bell’s palsy with oral acyclovir and predni-
solone.” Otology & neurotology : offi cial publication of the American Otological Society, 
American Neurotology Society and European Academy of Otology and Neurotology 24(6): 
948-951.
Hato, N., et al. (2008). ”Steroid and antiviral treatment for Bell’s palsy.” Lancet 371(9627): 1818-
1820.
Hato, N., et al. (2007). ”Valacyclovir and prednisolone treatment for Bell’s palsy: a multicenter, 
randomized, placebo-controlled study.” Otology & neurotology 28(3): 408-413.
Heffernan, C. and C. Jenkinson (2005). ”Measuring outcomes for neurological disorders: a review 
of disease-specifi c health status instruments for three degenerative neurological conditions.” 
Chronic illness 1(2): 131-142.
Ho, A. L., et al. (2012). ”Measuring quality of life and patient satisfaction in facial paralysis pa-
tients: a systematic review of patient-reported outcome measures.” Plastic and reconstruc-
tive surgery 130(1): 91-99.
Holland, J. and J. Bernstein (2011). ”Bell’s palsy.” Clinical evidence 2011.
Holland, N. J. and G. M. Weiner (2004). ”Recent developments in Bell’s palsy.” BMJ 329(7465): 
553-557.
House, J. W. (1983). ”Facial nerve grading systems.” The Laryngoscope 93(8): 1056-1069.
House, J. W. and D. E. Brackmann (1985). ”Facial nerve grading system.” Otolaryngology--head 
and neck surgery 93(2): 146-147.
Hsieh, R. L., et al. (2009). ”Correlates of degree of nerve involvement in early Bell’s palsy.” BMC 
neurology 9: 22.
Hu, W. L., et al. (2001). ”Reliability of the Sunnybrook Facial Grading System by novice users.” 
The Journal of otolaryngology 30(4): 208-211.
Hyden, D., et al. (1982). ”Prognosis in Bell’s palsy based on symptoms, signs and laboratory data.” 
Acta oto-laryngologica 93(5-6): 407-414.
Ikeda, M., et al. (2005). ”Clinical factors that infl uence the prognosis of facial nerve paralysis and 
the magnitudes of infl uence.” The Laryngoscope 115(5): 855-860.
Ikeda, M., et al. (2003). ”To what extent do evaluations of facial paralysis by physicians coincide 
with self-evaluations by patients: comparison of the Yanagihara method, the House-Brack-
mann method, and self-evaluation by patients.” Otology & neurotology 24(2): 334-338.
Kahn, J. B., et al. (2001). ”Validation of a patient-graded instrument for facial nerve paralysis: the 
FaCE scale.” The Laryngoscope 111(3): 387-398.
Kanerva, M., et al. (2006). ”Sunnybrook and House-Brackmann Facial Grading Systems: intrara-
ter repeatability and interrater agreement.” Otolaryngology--head and neck surgery 135(6): 
865-871.
Kasse, C. A., et al. (2005). ”The value of prognostic clinical data in Bell’s palsy.” Brazilian journal 
of otorhinolaryngology 71(4): 454-458.
Katusic, S. K., et al. (1986). ”Incidence, clinical features, and prognosis in Bell’s palsy, Rochester, 
Minnesota, 1968-1982.” Annals of neurology 20(5): 622-627.
Kawaguchi, K., et al. (2007). ”Reactivation of herpes simplex virus type 1 and varicella-zoster 
virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in 
patients with Bell’s palsy.” The Laryngoscope 117(1): 147-156.
Kennedy, P. G. (2010). ”Herpes simplex virus type 1 and Bell’s palsy-a current assessment of the 
controversy.” Journal of neurovirology 16(1): 1-5.
63
Kerbavaz, R. J., et al. (1983). ”The facial paralysis prognostic index.” Otolaryngology--head and 
neck surgery 91(3): 284-289.
Kohsyu, H., et al. (1994). ”Facial nerve enhancement in Gd-MRI in patients with Bell’s palsy.” Acta 
oto-laryngologica. Supplementum 511: 165-169.
Kress, B., et al. (2004). ”Bell palsy: quantitative analysis of MR imaging data as a method of pre-
dicting outcome.” Radiology 230(2): 504-509.
Lane, P. (2008). ”Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and 
MMRM approaches.” Pharmaceutical statistics 7(2): 93-106.
Lee, D. H., et al. (2006). ”Prognostic value of electroneurography in Bell’s palsy and Ramsay-
Hunt’s syndrome.” Clinical otolaryngology : offi cial journal of ENT-UK 31(2): 144-148.
Lee, H. Y., et al. (2012). ”Zoster sine herpete causing facial palsy.” American journal of otolaryngo-
logy 33(5): 565-571.
Lee, J., et al. (2007). ”Assessing impairment and disability of facial paralysis in patients with vesti-
bular schwannoma.” Archives of otolaryngology--head & neck surgery 133(1): 56-60.
Lewis, B. I. and K. K. Adour (1995). ”An analysis of the Adour-Swanson and House-Brackmann 
grading systems for facial nerve recovery.” European archives of oto-rhino-laryngology 
252(5): 265-269.
Linder, T., et al. (2005). ”Bell’s palsy and Herpes simplex virus: fact or mystery?” Otology & neu-
rotology 26(1): 109-113.
Linder, T. E., et al. (2010). ”The management of peripheral facial nerve palsy: ”paresis” versus ”pa-
ralysis” and sources of ambiguity in study designs.” Otology & neurotology 31(2): 319-327.
Liston, S. L. and M. S. Kleid (1989). ”Histopathology of Bell’s palsy.” The Laryngoscope 99(1): 
23-26.
Lockhart, P., et al. (2009). ”Antiviral treatment for Bell’s palsy (idiopathic facial paralysis).” Co-
chrane database of systematic reviews(4): CD001869.
Macgregor, F. C. (1990). ”Facial disfi gurement: problems and management of social interaction and 
implications for mental health.” Aesthetic plastic surgery 14(4): 249-257.
Malone, B. and R. H. Maisel (1988). ”Chapter 2. Anatomy of the facial nerve.” The American jour-
nal of otology 9(6): 494-504.
Mantsopoulos, K., et al. (2011). ”Predicting the long-term outcome after idiopathic facial nerve 
paralysis.” Otology & neurotology 32(5): 848-851.
May, M. (1970). ”Facial paralysis, peripheral type: a proposed method of reporting. (Emphasis on 
diagnosis and prognosis, as well as electrical and chorda tympani nerve testing).” The La-
ryngoscope 80(3): 331-390.
May, M., et al. (1983). ”Acute Bell’s palsy: prognostic value of evoked electromyography, maximal 
stimulation, and other electrical tests.” The American journal of otology 5(1): 1-7.
May, M. and C. D. Hawkins (1972). ”Bell’s palsy: results of surgery; salivation test versus nerve 
excitability test as a basis of treatment.” The Laryngoscope 82(7): 1337-1348.
May, M. and G. B. Hughes (1987). ”Facial nerve disorders: update 1987.” The American journal of 
otology 8(2): 167-180.
May M, S. B. (2000). The Facial Nerve, Anatomy for the clinician. New York, Thieme.
May, M., et al. (1976). ”The use of steroids in Bell’s palsy: a prospective controlled study.” The 
Laryngoscope 86(8): 1111-1122.
McAllister, K., et al. (2011). ”Surgical interventions for the early management of Bell’s palsy.” 
Cochrane database of systematic reviews(2): CD007468.
McCormick, D. P. (1972). ”Herpes-simplex virus as a cause of Bell’s palsy.” Lancet 1(7757): 937-
939.
64
Mehta, R. P. and T. A. Hadlock (2008). ”Botulinum toxin and quality of life in patients with facial 
paralysis.” Archives of facial plastic surgery : offi cial publication for the American Academy 
of Facial Plastic and Reconstructive Surgery, Inc. and the International Federation of Facial 
Plastic Surgery Societies 10(2): 84-87.
Melvin, T. A. and C. J. Limb (2008). ”Overview of facial paralysis: current concepts.” Facial plastic 
surgery : FPS 24(2): 155-163.
Mineta, M., et al. (1997). ”Prognosis and MRI fi ndings in patients with peripheral facial palsy.” 
Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica 57(3): 110-113.
Murakami, S., et al. (1996). ”Bell palsy and herpes simplex virus: identifi cation of viral DNA in 
endoneurial fl uid and muscle.” Annals of internal medicine 124(1 Pt 1): 27-30.
Murty, G. E., et al. (1994). ”The Nottingham System: objective assessment of facial nerve function 
in the clinic.” Otolaryngology--head and neck surgery 110(2): 156-161.
Peitersen, E. (1982). ”The natural history of Bell’s palsy.” The American journal of otology 4(2): 
107-111.
Peitersen, E. (2002). ”Bell’s palsy: the spontaneous course of 2,500 peripheral facial nerve palsies 
of different etiologies.” Acta oto-laryngologica. Supplementum(549): 4-30.
Pereira, L. M., et al. (2011). ”Facial exercise therapy for facial palsy: systematic review and meta-
analysis.” Clinical rehabilitation 25(7): 649-658.
Qiu, W. W., et al. (1996). ”Time course of Bell palsy.” Archives of otolaryngology--head & neck 
surgery 122(9): 967-972.
Robey, A. B. and M. C. Snyder (2011). ”Reconstruction of the paralyzed face.” Ear, nose, & throat 
journal 90(6): 267-275.
Romijn, M., et al. (2008). ”Medicinal treatment of Bell’s palsy: effect of prednisolone not suffi -
ciently demonstrated.” Nederlands tijdschrift voor geneeskunde 152(41): 2213-2215.
Roob, G., et al. (1999). ”Peripheral facial palsy: etiology, diagnosis and treatment.” European neu-
rology 41(1): 3-9.
Ross, B. G., et al. (1996). ”Development of a sensitive clinical facial grading system.” Otolaryngo-
logy--head and neck surgery 114(3): 380-386.
Rosson, G. D. and R. J. Redett (2008). ”Facial palsy: anatomy, etiology, grading, and surgical treat-
ment.” Journal of reconstructive microsurgery 24(6): 379-389.
Rowlands, S., et al. (2002). ”The epidemiology and treatment of Bell’s palsy in the UK.” European 
journal of neurology 9(1): 63-67.
Ryzenman, J. M., et al. (2005). ”Facial paralysis and surgical rehabilitation: a quality of life analysis 
in a cohort of 1,595 patients after acoustic neuroma surgery.” Otology & neurotology 26(3): 
516-521; discussion 521.
Saito, D. M. and S. W. Cheung (2010). ”A comparison of facial nerve disability between patients 
with Bell’s palsy and vestibular schwannoma.” Journal of clinical neuroscience 17(9): 1122-
1125.
Salinas, R. A., et al. (2010). ”Corticosteroids for Bell’s palsy (idiopathic facial paralysis).” Cochrane 
database of systematic reviews(3): CD001942.
Sathirapanya, P. and C. Sathirapanya (2008). ”Clinical prognostic factors for treatment outcome in 
Bell’s palsy: a prospective study.” Journal of the Medical Association of Thailand = Chot-
maihet thangphaet 91(8): 1182-1188.
Satoh, Y., et al. (2000). ”A comparison and conversion table of ’the House-Brackmann facial nerve 
grading system’ and ’the Yanagihara grading system’.” Auris, nasus, larynx 27(3): 207-212.
Simpson, H. B., et al. (2008). ”Statistical choices can affect inferences about treatment effi cacy: a 
case study from obsessive-compulsive disorder research.” Journal of psychiatric research 
42(8): 631-638.
65
Smith, I. M., et al. (1988). ”Idiopathic facial (Bell’s) palsy: a clinical survey of prognostic factors.” 
Clinical otolaryngology and allied sciences 13(1): 17-23.
Smith, I. M., et al. (1994). ”An out-patient review of facial palsy in the community.” Clinical otola-
ryngology and allied sciences 19(3): 198-200.
Stennert, E., et al. (1977). ”[An index for paresis and defective healing--an easily applied method for 
objectively determining therapeutic results in facial paresis (author’s transl)].” HNO 25(7): 
238-245.
Stjernquist-Desatnik, A., et al. (2006). ”Detection of herpes simplex and varicella-zoster viruses in 
patients with Bell’s palsy by the polymerase chain reaction technique.” The Annals of oto-
logy, rhinology, and laryngology 115(4): 306-311.
Streiner, D. L. (2002). ”The case of the missing data: methods of dealing with dropouts and other 
research vagaries.” Canadian journal of psychiatry. Revue canadienne de psychiatrie 47(1): 
68-75.
Sullivan, F. M., et al. (2007). ”Early treatment with prednisolone or acyclovir in Bell’s palsy.” The 
New England journal of medicine 357(16): 1598-1607.
Takasu, T., et al. (1992). ”Detection of latent herpes simplex virus DNA and RNA in human geni-
culate ganglia by the polymerase chain reaction.” Acta oto-laryngologica 112(6): 1004-1011.
Takemoto, N., et al. (2011). ”Prognostic factors of peripheral facial palsy: multivariate analysis 
followed by receiver operating characteristic and Kaplan-Meier analyses.” Otology & neu-
rotology 32(6): 1031-1036.
Teixeira, L. J., et al. (2011). ”Physical therapy for Bell’s palsy (idiopathic facial paralysis).” Co-
chrane database of systematic reviews(12): CD006283.
Terzis, J. K. and K. Tzafetta (2009). ””Babysitter” procedure with concomitant muscle transfer in 
facial paralysis.” Plastic and reconstructive surgery 124(4): 1142-1156.
Thomander, L. and E. Stalberg (1981). ”Electroneurography in the prognostication of Bell’s palsy.” 
Acta oto-laryngologica 92(3-4): 221-237.
Tiemstra, J. D. and N. Khatkhate (2007). ”Bell’s palsy: diagnosis and management.” American 
family physician 76(7): 997-1002.
Ushio, M., et al. (2008). ”Prediction of the prognosis of Bell’s palsy using multivariate analyses.” 
Otology & neurotology 29(1): 69-72.
Valls-Sole, J. (2007). ”Electrodiagnostic studies of the facial nerve in peripheral facial palsy and 
hemifacial spasm.” Muscle & nerve 36(1): 14-20.
VanSwearingen, J. M. and J. S. Brach (1996). ”The Facial Disability Index: reliability and validity 
of a disability assessment instrument for disorders of the facial neuromuscular system.” 
Physical therapy 76(12): 1288-1298; discussion 1298-1300.
VanSwearingen, J. M., et al. (1998). ”Psychological distress: linking impairment with disability in 
facial neuromotor disorders.” Otolaryngology--head and neck surgery 118(6): 790-796.
Yanagihara (1976). Grading of facial palsy. Third International Symposium on Facial Nerve Sur-
gery, Zurich, Aesculapius, Birmingham.
Yanagihara, N. (1988). ”Incidence of Bell’s palsy.” The Annals of otology, rhinology & laryngology. 
Supplement 137: 3-4.
Yanagihara, N., et al. (2000). ”Edematous swelling of the facial nerve in Bell’s palsy.” Acta oto-
laryngologica 120(5): 667-671.
Yeo, S. W., et al. (2007). ”Analysis of prognostic factors in Bell’s palsy and Ramsay Hunt syn-
drome.” Auris, nasus, larynx 34(2): 159-164.
